morbid
mortal
social
disrupt
due
acquir
immunodefici
syndrom
aid
pandem
weigh
disproportion
upon
resourcepoor
area
tropic
consequ
potenti
interact
human
immunodefici
viru
hiv
infect
tropic
infecti
diseas
great
interact
mark
epidemiolog
complex
aid
pandem
best
describ
sum
discontinu
overlap
epidem
diseas
among
popul
variabl
vari
risk
see
chapter
predomin
mode
transmiss
hiv
perinat
sexual
parenter
result
bimod
distribut
diseas
peak
among
young
children
young
adult
risk
infect
diseas
due
tropic
pathogen
vari
wide
differ
ecolog
polit
socioeconom
condit
includ
access
medic
care
relat
specif
host
factor
age
exposur
pregnanc
behavior
nutrit
host
genet
diseas
due
coinfect
pathogen
may
due
primari
infect
recurr
infect
reactiv
latent
infect
pathogen
risk
factor
respons
acquisit
hiv
may
also
risk
factor
respons
acquisit
coinfect
pathogen
consequ
epidemiolog
complex
preval
express
coinfect
variabl
across
ecolog
econom
polit
behavior
cultur
divid
infect
hiv
influenc
natur
histori
infect
pathogen
facilit
infect
alter
incid
diseas
increas
ratio
diseas
infect
chang
present
diseas
exacerb
cours
diseas
effect
primarili
result
immunosuppress
associ
hiv
infect
abnorm
immun
function
found
essenti
everi
cellular
function
compart
immun
system
aid
although
profound
defect
cellmedi
immun
cmi
appear
greatest
clinic
import
vitro
correl
includ
function
abnorm
cell
progress
failur
prolifer
interleukin
il
product
dysregul
express
molecul
essenti
tcellantigen
present
cell
interact
abnorm
activationinduc
apoptosi
preferenti
loss
cell
gastrointestin
gi
tract
expans
regulatori
cell
potent
inhibitor
immun
respons
self
pathogen
monocytemacrophag
decreas
chemotaxi
intracellular
microbicid
activ
abnorm
cytokin
product
dendrit
cell
reduc
abil
present
antigen
activ
cell
along
effici
transfer
hiv
infect
cell
deplet
plasmacytoid
dendrit
cell
popul
cell
decreas
cytotox
tlymphocyt
ctl
function
abnorm
activationinduc
apoptosi
natur
killer
nk
cell
decreas
prolifer
product
dysregul
humor
immun
mark
polyclon
bcell
activ
also
seen
function
abnorm
tcell
macrophag
dendrit
cell
function
thought
paramount
suppress
cmi
opportunist
infect
oi
seen
patient
aid
addit
direct
effect
hiv
infect
immun
system
hivinfect
peopl
may
also
compromis
clinic
signific
way
profound
nutrit
metabol
derang
eg
wast
slim
diseas
therapeut
intervent
eg
corticosteroid
use
treatment
pneumocysti
pneumonia
immun
abnorm
associ
secondari
infect
eg
suppress
cmi
seen
viscer
leishmaniasi
vl
list
infecti
diseas
exacerb
hiv
coinfect
includ
mani
predict
data
demonstr
import
role
cmi
protect
etiolog
agent
sever
pathogen
immun
presum
depend
cmi
appear
exacerb
hiv
coinfect
howev
hiv
experi
natur
caus
reexamin
immunolog
miss
infect
aid
hiv
infect
also
influenc
therapeut
respons
patient
vari
tropic
infect
abil
diagnos
monitor
coinfect
may
compromis
aberr
serolog
respons
includ
fals
posit
due
polyclon
bcell
activ
fals
neg
due
blunt
antigenspecif
antibodi
respons
newli
acquir
pathogen
fals
serolog
revers
treatment
late
hiv
diseas
diagnosi
may
also
hinder
unusu
present
diseas
coinfect
pathogen
final
plethora
intercurr
patholog
condit
may
lead
dull
ockham
razor
diseas
evalu
aid
patient
singl
pathogen
multipl
pathogen
hiv
infect
side
effect
therapeut
drug
combin
may
respons
present
complaint
given
suboptim
respons
chemotherapi
mani
infect
presenc
profound
immunosuppress
drug
may
need
given
greater
number
longer
durat
mani
pathogen
absenc
immun
reconstitut
result
highli
activ
antiretrovir
therapi
haart
lifelong
suppress
therapi
necessari
drug
therapi
approach
patient
hiv
coinfect
tropic
infecti
diseas
hivinfect
patient
may
complic
increas
rate
drug
allergi
well
untoward
drug
interact
set
polypharmaci
prophylaxi
coinfect
may
compromis
substandard
vaccin
respons
final
presenc
hiv
coinfect
complic
public
health
consequ
tropic
diseas
aid
may
increas
transmiss
secondari
infect
provid
fertil
soil
develop
drug
resist
public
health
resourc
devot
aid
pandem
may
divert
resourc
away
control
prevent
infecti
diseas
presenc
hiv
coinfect
lead
diseas
markedli
greater
incid
sever
standard
definit
oi
tropic
infecti
diseas
leishmaniasi
american
trypanosomiasi
coinfect
also
demonstr
subtl
effect
cours
diseas
tropic
agent
schistosoma
mansoni
robust
alter
found
natur
histori
mani
tropic
infect
includ
nematod
organ
latter
group
current
absenc
evid
signific
effect
hiv
express
diseas
respons
treatment
constru
strong
evid
absenc
effect
research
resourc
spent
understand
clinic
epidemiolog
manifest
hiv
pandem
industri
countri
tropic
infecti
diseas
underrepres
coinfect
hiv
endem
tropic
diseas
mark
low
preval
subtleti
interact
diagnost
difficulti
low
research
prioriti
presenc
signific
interact
like
miss
exampl
despit
research
prioriti
among
tropic
infect
accord
malaria
first
signific
interact
appreci
hiv
infect
lack
benefit
increas
pariti
control
malaria
pregnant
women
discov
year
aid
epidem
recogn
less
heavili
studi
pathogen
compar
subtl
interact
like
emerg
time
research
resourc
appropri
direct
focus
oi
may
help
highlight
clearest
data
clinic
express
aid
tropic
agent
known
caus
oi
aid
patient
sever
classic
tropic
pathogen
mostli
found
among
intracellular
protozoan
bacteria
endem
fungi
mark
absenc
metazoan
overal
clinic
express
aid
mani
resourcepoor
area
tropic
appear
involv
differ
spectrum
oi
common
north
america
europ
place
high
incid
pneumocysti
pneumonia
dissemin
mycobacterium
avium
cytomegaloviru
cmv
found
resourcerich
north
clinic
express
aid
much
tropic
mark
frequent
tuberculosi
common
seriou
aid
oi
world
chronic
diarrhea
wast
chronic
fever
without
obviou
local
sourc
pulmonari
diseas
contribut
predominantli
tropic
pathogen
latter
common
syndrom
unclear
illumin
problem
much
avail
data
hiv
diseas
tropic
understand
spectrum
aidsassoci
oi
given
area
depend
presenc
adequ
surveil
system
often
lack
resourcepoor
region
tropic
presenc
inadequ
infrastructur
limit
financi
resourc
difficult
access
medic
care
part
social
disadvantag
surveil
like
sporad
involv
mainli
sampl
subgroup
aid
patient
late
stage
diseas
resourc
limit
diagnost
report
like
bias
favor
oi
inexpens
diagnos
misdiagnos
even
common
impress
progress
aid
rapid
subsaharan
africa
industri
countri
rest
data
less
robust
rapid
observ
cours
presum
due
higher
frequenc
virul
coinfect
problem
nutrit
access
medic
care
may
repres
larg
part
systemat
bia
favor
later
initi
diagnosi
hiv
infect
aid
convers
suggest
burden
ill
mortal
earli
hiv
diseas
often
unrecogn
due
highgrad
pathogen
streptococcu
pneumonia
mycobacterium
tuberculosi
salmonella
may
rival
due
oi
latestag
aid
tropic
hiv
shed
light
mani
previous
obscur
human
pathogen
enter
microsporidian
unknown
agent
human
diseas
prior
aid
epidem
other
crypto
sporidium
parvum
underappreci
caus
diseas
normal
host
preval
aid
patient
led
systemat
studi
normal
host
theoret
experiment
reason
believ
coinfect
significantli
alter
cours
hiv
pathogenesi
central
role
ongo
viral
replic
hiv
pathogenesi
firmli
establish
set
point
concentr
plasma
viremia
correl
well
longterm
clinic
outcom
presum
increas
viral
replic
potenti
acceler
cours
diseas
effici
replic
hiv
cell
depend
cellular
activ
similarli
activ
macrophag
dendrit
cell
stimul
hiv
replic
increas
transcript
factor
bind
hiv
long
termin
repeat
region
enhanc
transcript
coinfect
pathogen
stimul
immun
cell
activ
either
directli
eg
stimul
signal
tolllik
receptor
upregul
transcript
factor
transactiv
coinfect
immun
cell
indirectli
eg
promot
gener
proinflammatori
cytokin
activ
cell
part
adapt
immun
respons
immun
activ
also
lead
upregul
express
hiv
coreceptor
therebi
facilit
infect
fresh
cell
immunolog
respons
pathogen
well
purifi
vaccin
antigen
clearli
potenti
enhanc
dynam
burden
hiv
replic
vitro
studi
divers
pathogen
provid
mechanist
support
idea
experiment
evid
also
suggest
immun
activationdriven
augment
hiv
viral
burden
occur
vivo
also
circumstanti
evid
immun
activ
may
enhanc
hiv
pathogenesi
point
remain
somewhat
controversi
howev
whether
immun
activationrel
increas
viral
load
actual
acceler
pathogenesi
hiv
may
depend
whether
chang
transient
immun
treat
acut
infect
chronic
untreat
infect
reset
set
point
plasma
viremia
particular
coinfect
direct
equat
immun
activ
upregul
hiv
replic
simplist
howev
cell
mechan
activ
appear
critic
whether
viral
replic
induc
suppress
furthermor
activ
proinflammatori
cytokin
product
posit
effect
hiv
replic
goe
hand
hand
activ
antiinflammatori
cytokin
product
inhibit
hiv
replic
gener
immun
respons
reliabl
induc
counterregulatori
respons
may
well
suppress
hiv
replic
thu
surpris
vitro
studi
provid
mechanist
support
abil
coinfect
pathogen
suppress
hiv
replic
inde
wherea
infect
tropic
pathogen
eg
plasmodium
falciparum
shown
increas
plasma
hiv
load
overal
effect
acut
coinfect
pathogen
includ
measl
viru
dengu
viru
orientia
tsutsugamushi
may
decreas
hiv
viral
load
said
measur
persist
immun
activ
broadli
taken
shown
correl
independ
plasma
viral
load
steeper
slope
tcell
deplet
diseas
progress
mortal
risk
respons
mechan
remain
underdefin
coinfect
may
thu
favor
progress
hiv
diseas
independ
effect
viral
dynam
context
provoc
find
hiv
infect
lead
sustain
system
exposur
microbi
product
gut
someth
may
well
abet
tropic
gut
lumin
tissu
pathogen
potenti
special
import
three
trial
procedur
seem
biolog
tenuou
suggest
signific
least
shortterm
benefit
deworm
plasma
mrna
load
tcell
count
overal
hypothesi
thu
remain
compel
howev
given
shortterm
followup
variabl
biolog
epidemiolog
differ
organ
differ
intervent
use
trial
clearest
conclus
made
data
subject
need
someth
underscor
recent
alarm
report
matern
helminth
coinfect
associ
significantli
increas
risk
mothertochild
transmiss
hiv
infect
effect
coinfect
perhap
concret
tropic
diseas
may
lead
directli
increas
risk
infect
hiv
treatment
sever
anemia
induc
malaria
led
hiv
infect
countless
children
transfus
genit
schistosomiasi
like
genit
inflammatori
condit
appear
increas
effici
hiv
transmiss
basic
biolog
hiv
progress
diagnosi
treatment
hiv
diseas
epidemiolog
hivaid
tropic
discuss
chapter
chapter
focus
tropic
infecti
diseas
may
oi
hivinfect
patient
oi
common
industri
world
discuss
depth
unless
compel
clinic
epidemiolog
reason
multipl
refer
avail
discuss
cosmopolitan
oi
inform
specif
organ
discuss
found
cite
pathogenspecif
chapter
diagnost
prophylact
therapeut
recommend
discuss
describ
approach
hiv
patient
limit
scarc
medic
resourc
like
mani
strategi
deal
hiv
diseas
evolv
affluent
industri
countri
includ
hightechnolog
diagnost
multidrug
chemoprophylaxi
mani
recommend
may
easili
translat
resourcepoor
area
tropic
malaria
malaria
see
chapter
remain
one
import
infecti
diseas
world
today
evid
mous
human
studi
suggest
import
role
cell
protect
immun
bloodstag
malaria
larg
area
share
endem
medic
signific
interact
hiv
malaria
thu
expect
fear
initi
studi
neg
falciparum
malaria
appear
oi
acceler
progress
hiv
diseas
howev
followup
studi
reveal
complex
bidirect
interact
p
falciparum
hiv
remain
littl
inform
interact
hiv
p
vivax
p
malaria
p
oval
p
knowlesi
epidemiolog
immunobiolog
p
falciparum
integr
complex
sever
diseas
death
due
p
falciparum
occur
lack
specif
acquir
immun
someth
develop
face
high
rate
transmiss
time
stabl
heavi
transmiss
greatest
burden
diseas
occur
young
children
travel
pregnant
women
latter
reason
discuss
nonpregn
adult
tend
parasitem
absenc
symptom
unstabl
low
transmiss
rate
relationship
parasitemia
diseas
tend
direct
burden
diseas
fall
equal
might
expect
interact
p
fal
ciparum
hiv
vari
malaria
transmiss
dynam
first
signific
clinic
effect
hiv
malaria
found
set
pregnanc
area
high
malari
endem
despit
agedepend
induct
immun
sever
diseas
area
pregnant
women
heighten
vulnerablil
asymptomat
addit
viral
sequela
gener
immunolog
activ
induct
specif
alter
immunoregulatori
environ
host
ubiquit
tropic
pathogen
postul
acceler
cours
hiv
crossregul
subset
cell
distinguish
cytokin
profil
function
activ
cell
produc
among
cytokin
import
classic
macrophag
activ
develop
cmi
gener
humor
respons
involv
complementfix
antibodi
isotyp
cell
produc
among
cytokin
import
altern
macrophag
activ
gener
immunoglobulin
e
ige
respons
eosinophilia
mast
cell
respons
atopi
immunolog
respons
helminth
parasit
domin
cytokin
product
mous
model
shown
helminthdriven
polar
shift
immunolog
respons
heterolog
antigen
pathogen
pattern
well
significantli
suppress
tcellmedi
viral
clearanc
respons
also
found
impair
antigenspecif
immun
respons
mice
human
chronic
helminth
infect
widespread
tropic
result
prime
immun
system
may
favor
progress
hiv
diseas
sever
mechan
postul
first
immun
system
may
directli
suppress
tcellmedi
antihiv
respons
second
hiv
appear
replic
preferenti
cell
someth
may
well
due
increas
express
cytidin
deaminas
antihiv
activ
cell
third
cell
hivseroposit
peopl
undergo
abnorm
activationinduc
apoptosi
thought
play
role
deplet
cell
time
cytokin
amplifi
activationinduc
apoptosi
fourth
cytokin
upregul
hiv
coreceptor
express
cell
monocytemacrophag
note
demonstr
peripher
blood
cell
patient
intestin
helminth
infect
suscept
vitro
infect
hiv
cell
helminthuninfect
patient
fifth
divers
chronic
helminth
infect
associ
develop
strong
immun
counterregulatori
respons
may
blunt
heterolog
antihiv
immun
respons
final
tissu
trematod
eg
schistosom
lumin
nematod
eg
geohelminth
like
effect
gut
mucos
permeabl
someth
may
drive
immun
activ
diseas
progress
increas
system
exposur
gutderiv
microbi
product
thu
clear
biolog
plausibl
hypothesi
endem
helminth
coinfect
lead
acceler
hiv
diseas
cours
tropic
hypothesi
difficult
clearli
address
experiment
initi
studi
ethiopia
indic
hiv
viral
load
significantli
higher
individu
variou
helminth
infect
individu
without
helminth
correl
posit
parasit
load
well
decreas
elimin
worm
antiparasit
treatment
subsequ
sever
similar
studi
southern
africa
fail
replic
find
one
studi
even
report
signific
transient
increas
viral
load
therapi
schistosomiasi
cochran
review
analyz
three
random
control
trial
publish
date
effect
anthelminth
therapi
hiv
diseas
progress
antiretrovir
patient
random
trial
praziquantel
schistosomiasi
found
signific
benefit
treatment
plasma
rna
load
lack
increas
treatment
compar
increas
viral
load
absenc
treatment
nonsignific
trend
toward
benefici
effect
count
hivinfect
individu
random
doubleblind
placebocontrol
crossov
trial
diethylcarbamazin
bancroftian
filariasi
report
decreas
plasma
rna
load
nonsignific
trend
toward
benefici
effect
count
treatment
random
doubleblind
placebocontrol
trial
albendazol
infect
divers
geohelminth
includ
hookworm
ascari
trichuri
found
nonsignific
trend
toward
benefici
effect
treatment
plasma
rna
load
signific
benefit
treatment
tcell
count
specif
subset
patient
ascari
infect
pool
data
approach
patient
hiv
coinfect
tropic
infecti
diseas
pharmacolog
interact
antiretrovir
antimalari
recogn
studi
vitro
number
proteas
inhibitor
pi
well
nonnucleosid
revers
transcriptas
inhibitor
delaviradin
efavirenz
inhibit
hepat
cytochrom
enzym
princip
effect
isoform
ritonavir
potent
inhibitor
although
isoform
may
also
affect
nevirapin
efavirenz
caus
secondari
induct
effect
ritonavir
nelfinavir
well
antimalari
agent
larg
metabol
via
enzym
mefloquin
appear
except
although
detail
remain
poorli
understood
proguanil
chloroquin
metabol
appear
larg
isoform
respect
chloroquin
also
undergo
appreci
renal
excret
wherea
doxycyclin
larg
avoid
pathway
howev
note
interact
vitro
observ
unknown
whether
theoret
consider
practic
consequ
vivo
publish
pharmacokinet
data
suggest
signific
drugdrug
interact
nelfinavir
indinavir
mefloquin
ritonavir
minim
effect
mefloquin
pharmacokinet
wherea
mefloquin
suppress
ritonavir
plasma
level
atovaquon
increas
serum
zidovudin
azt
level
approxim
although
azt
effect
pharmacokinet
atovaquon
summari
actual
pharmacokinet
easili
predict
theoret
consider
pauciti
data
base
current
data
mefloquin
doxycyclin
chloroquin
malaron
atovaquon
proguanil
like
safe
retain
efficaci
prophylaxi
sensit
strain
malaria
among
malaria
treatment
option
quinidin
quinin
possibl
artemesinin
compound
predominantli
metabol
isoform
larg
threefold
increas
area
curv
quinidin
expect
ritonavir
result
quinidin
consid
contraind
ritonavir
like
appli
quinin
well
actual
clinic
data
howev
whether
clinic
relev
effect
pi
metabol
artemisinin
compound
depend
least
part
remain
unknown
uncompl
malaria
probabl
safe
treat
mefloquin
region
suscept
strain
atovaquoneproguanil
artemesinin
plu
doxycylin
use
quinin
quinidin
artemisinin
compound
remain
essenti
parenter
therapi
sever
chloroquineresist
malaria
ritonavir
andor
pi
delaviridin
efavirenz
normal
load
dose
quinin
quinidin
probabl
given
along
reduct
mainten
infus
dose
obvious
care
monitor
need
done
potenti
fatal
arrhythm
consequ
quininequinidin
overdosag
set
given
lack
data
howev
underdos
may
also
potenti
problem
washout
period
metabol
effect
ritonavir
thought
hour
recent
guidelin
malaria
treatment
recommend
artemesininbas
combin
therapi
contain
artemeth
lumefantrin
artesun
amodiaquin
mefloquin
sulfadoxinepyrimethamin
firstlin
treatment
uncompl
malaria
malariaendem
region
firstlin
treatment
hiv
infect
includ
antiretrovir
therapi
contain
efavirenz
found
elev
amodiaquin
level
halflif
find
rais
concern
safeti
combin
treatment
question
addit
rare
occurr
amodiaquinerel
hepatotox
along
report
neutropenia
hivinfect
children
treat
artesun
plu
amodiaquin
caus
concern
higher
incid
allerg
respons
sulfonamid
make
pyrimethaminesulfadoxin
less
attract
malaria
therapi
hivseroposit
patient
least
north
american
popul
furthermor
stevensjohnson
syndrom
relat
advers
mucocutan
reaction
longact
sulfa
compound
sulfadoxin
contraind
use
malaria
prophylaxi
develop
countri
presenc
hiv
infect
alter
predict
valu
fever
empir
diagnosi
malaria
area
high
preval
hiv
malaria
common
practic
empir
treat
febril
symptomat
parasitemia
placent
vasculatur
shield
parasit
erythrocyt
system
immun
respons
allow
local
parasit
replic
placent
parasitemia
associ
low
birth
weight
increas
infant
mortal
uteroplacent
immun
respons
restrict
parasit
replic
howev
effect
respons
increas
subsequ
pregnanc
pressur
recurr
malari
exposur
parityacquir
immun
p
falciparum
delay
impair
presenc
hiv
infect
turn
benefici
effect
matern
placent
neonat
pariti
control
parasitemia
pregnanc
markedli
attenu
face
hiv
coinfect
hiv
infect
associ
increas
rate
level
peripher
placent
parasitemia
clinic
malaria
matern
anemia
pregnant
women
coinfect
associ
higher
risk
low
birth
weight
preterm
birth
intrauterin
growth
retard
postnat
infant
mortal
although
placent
parasitemia
associ
increas
placent
hiv
viral
load
coinfect
patient
remain
unclear
whether
increas
risk
mothertochild
transmiss
hiv
conflict
result
enhanc
protect
effect
publish
world
health
organ
technic
consult
recommend
hivinfect
pregnant
women
risk
malaria
use
insecticidetr
bednet
along
accord
hiv
stage
either
intermitt
prevent
treatment
sulfadoxinepyrimethamin
higher
dose
recommend
nonpregn
popul
daili
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
area
unstabl
transmiss
p
falciparum
hiv
coinfect
risk
factor
sever
malaria
adult
young
children
area
heavi
transmiss
hiv
infect
thought
also
risk
factor
sever
malaria
children
although
clear
data
lack
contrast
presenc
hiv
coinfect
seem
modest
impact
risk
parasitemia
clinic
malaria
semiimmun
adult
area
risk
increas
decreas
tcell
number
correl
less
strong
hivrel
oi
acquir
immun
import
therapeut
clearanc
drugresist
parasit
one
might
predict
hiv
infect
hinder
respons
antimalari
therapi
particularli
suboptim
adult
area
heavi
transmiss
recent
data
support
hiv
coinfect
also
found
associ
increas
risk
reinfect
success
treatment
malaria
whether
due
immunosuppressionassoci
compromis
immun
respons
liverstag
parasit
increas
frequenc
bite
anophel
mosquito
presenc
hivassoci
febril
diseas
unclear
daili
prophylaxi
tmpsmx
recommend
children
adult
subsaharan
africa
tcell
count
mm
led
decreas
febril
malaria
episod
frequenc
studi
uganda
fact
addit
antiretrovir
therapi
associ
decreas
episod
provid
biolog
support
link
hiv
infect
vulner
diseas
p
falciparum
use
insecticidetr
bednet
lower
risk
hiv
replic
peripher
blood
cell
enhanc
exposur
p
falciparum
antigen
vitro
part
induct
hivuninfect
peripher
blood
mononuclear
cell
challeng
malari
sporozoit
extract
exhibit
increas
susceptibl
hiv
infect
peripher
blood
mononuclear
cell
hivinfect
individu
exhibit
higher
level
hiv
replic
exposur
parasit
antigen
increas
hiv
replic
dendrit
cell
also
seen
vivo
infect
p
chabaudi
mice
transgen
hiv
genom
might
therefor
expect
p
falciparum
infect
shown
associ
increas
hiv
viral
burden
peripher
well
placent
blood
malaria
treatment
associ
reduct
plasma
hiv
viral
load
although
viral
burden
remain
elev
compar
control
durat
studi
whether
malariamedi
increas
hiv
replic
acceler
cours
hiv
diseas
remain
determin
isol
recov
hivinfect
patient
previous
encount
immunocompet
peopl
either
vl
cutan
leishmaniasi
cl
find
certain
strain
leishmania
typic
caus
cutan
diseas
recov
bone
marrow
coinfect
patient
could
support
either
primari
reactiv
hypothesi
normal
age
distribut
vl
caus
l
donovani
includ
adult
well
children
contrast
vl
due
l
infantum
affect
children
predominantli
often
age
year
younger
spain
intraven
drug
use
account
major
hivleishmania
coinfect
age
distribut
vl
revers
case
occur
young
adult
male
fact
half
patient
demonstr
organ
peripher
blood
smear
fact
sandfli
readili
infect
feed
coinfect
patient
provid
evid
addit
anthroponot
cycl
transmiss
set
summari
although
reactiv
latent
leishmani
infect
difficult
exclud
increas
evid
southern
europ
least
favor
primari
infect
certain
strain
leishmania
main
mechan
coinfect
hivaid
spread
hiv
pandem
increas
epidemiolog
overlap
area
hiv
leishmaniasi
occur
case
report
approxim
countri
although
bulk
case
report
southern
europ
note
rel
case
american
mucocutan
leishmaniasi
recogn
hivinfect
subject
propens
dissemin
diseas
presenc
hiv
appear
limit
certain
speci
leishmania
bulk
inform
vl
complic
hiv
infect
involv
l
infantum
mediterranean
region
presum
abil
viscer
influenc
hiv
also
appli
l
donovani
southern
asia
africa
l
chagasi
latin
america
howev
document
still
somewhat
meager
one
possibl
reason
poor
overlap
geograph
distribut
leishmaniasi
caus
speci
distribut
well
preval
hiv
infect
speci
leishmania
caus
cl
implic
rare
oi
hivaid
one
instanc
l
braziliensi
recov
bone
marrow
patient
tcell
count
less
main
clinic
pictur
case
well
other
includ
patient
infect
l
major
one
multipl
cutan
lesion
resembl
diffus
cl
diffus
cl
also
report
part
immun
reconstitut
inflammatori
syndrom
iri
febril
ill
longer
week
durat
hivinfect
person
lifetim
histori
travel
leishmaniaendem
region
world
rais
suspicion
leishmaniasi
complic
hiv
infect
patient
intraven
drug
user
travel
southern
europ
especi
spain
franc
itali
would
particularli
pertin
clinic
diagnosi
vl
leishmaniahiv
coinfect
peopl
may
difficult
hivinfect
patient
oppos
nonhivinfect
patient
exhibit
characterist
clinic
pattern
name
fever
splenomegali
hepatomegali
increas
immunosuppress
clinic
evid
ectop
local
parasit
becom
common
gastrointestin
laryng
pulmonari
periton
involv
report
singl
multipl
cutan
form
andor
mucos
mucocutan
lesion
also
describ
aid
patient
worldwid
immunocompet
peopl
serolog
test
use
diagnosi
vl
bcell
activ
promin
larg
amount
specif
nonspecif
antibodi
produc
contrast
approxim
coinfect
patient
lack
detect
antibodi
level
situat
may
differ
instanc
leishmani
infect
preced
hiv
infect
impair
immun
respons
ensu
gradoni
associ
suggest
type
serolog
data
could
use
indic
sequenc
acquisit
two
infect
support
concept
provid
report
ethiopia
seven
case
vl
hiv
coinfect
highli
elev
antileishmani
antibodi
titer
patient
live
mani
year
leishmaniasisendem
area
ethiopia
adult
malaria
lead
gross
overestim
overtreat
malaria
final
treatment
sever
anemia
due
malaria
one
common
reason
blood
transfus
subsaharan
africa
malaria
thu
provid
indirect
import
risk
factor
acquisit
hiv
infect
children
blood
suppli
well
screen
hiv
babesiosi
signific
clinic
interact
hiv
infect
suggest
babesia
microti
see
chapter
rais
possibl
infect
tropic
babesi
speci
may
risk
aid
patient
hand
report
case
b
microti
infect
hivinfect
peopl
two
occur
splenectom
patient
one
chronic
lowlevel
hemolysi
due
babesia
prior
splenectomi
like
patient
intact
spleen
present
fever
unknown
origin
face
count
less
quinin
plu
clindamycin
atovaquon
plu
azithromycin
appear
therapeut
efficaci
acut
diseas
face
hiv
infect
chronic
suppress
therapi
appear
indic
vectorborn
diseas
vector
avoid
effici
way
prevent
diseas
signific
interact
hiv
infect
remain
describ
european
bovin
babesia
speci
b
bovi
b
divergen
emerg
agent
human
babesiosi
north
america
except
toxoplasma
gondii
leishmania
speci
see
chapter
common
tissu
protozoa
caus
oi
patient
aid
surpris
cmi
particular
immun
respons
critic
protect
leishmania
compet
axi
cellular
respons
becom
increasingli
compromis
progress
hivrel
immunosuppress
vivo
overal
loss
immunolog
control
parasit
infect
reflect
oftenaberr
manifest
vl
aid
includ
peripher
parasitemia
found
parasit
dissemin
unusu
bodi
compart
aidsrel
oi
occur
low
tcell
count
leishmaniasi
may
due
either
primari
infect
reactiv
clinic
latent
infect
although
publish
data
interact
hiv
leishmania
focu
larg
effect
hiv
leishmani
infect
diseas
also
vitro
vivo
evid
leishmania
augment
hiv
replic
leishmania
normal
requir
arthropod
vector
sandfli
move
zoonot
cycl
human
host
certain
speci
leishmania
l
tropica
l
donovani
locat
eg
syria
india
respect
anthroponot
humantohuman
cycl
via
sandfli
exist
situat
intraven
drug
use
practic
transmiss
simplifi
even
direct
persontoperson
transfer
via
contamin
needl
syring
gener
howev
leishmaniasi
rural
periurban
zoonosi
experi
vl
complic
hivaid
mediterranean
countri
indic
mani
perhap
leishmani
infect
acquir
hiv
hiv
infect
alreadi
occur
transmiss
agent
occur
share
needl
syring
intraven
drug
user
could
theoret
reduc
aggress
program
educ
provis
clean
needl
syring
effect
program
sandfli
vector
control
interrupt
transmiss
heavili
infect
human
reservoir
human
well
usual
cycl
infect
dog
human
vector
control
also
way
prevent
coinfect
leishmania
acquir
hiv
sexual
rel
high
preval
latent
leishmani
infect
would
appear
reactiv
latent
infect
could
account
increas
number
hivleishmania
coinfect
howev
concept
alway
support
epidemiolog
evid
greater
variabl
zymodem
enzym
marker
found
parasit
isol
hivinfect
uninfect
patient
one
seri
five
approach
patient
hiv
coinfect
tropic
infecti
diseas
featur
diseas
similar
toxoplasm
meningoenceph
enlarg
hemorrhag
foci
produc
mass
effect
simul
brain
tumor
lesion
often
multipl
comput
tomograph
ct
scan
magnet
reson
imag
mri
show
ring
enhanc
preferenti
involv
white
matter
toxoplasm
enceph
may
coexist
patient
cerebrospin
fluid
csf
find
includ
slight
pleocytosi
increas
protein
slightli
decreas
glucos
patient
presenc
trypanosom
histolog
brain
lesion
show
necrot
foci
hemorrhag
infiltr
inflammatori
cell
amastigot
form
parasit
abund
glial
cell
macrophag
occasion
neuron
cell
myocard
common
autopsi
find
die
aidsrel
cruzi
meningoenceph
myocard
often
clinic
silent
clinic
manifest
present
involv
arrhythmia
congest
heart
failur
diagnosi
reactiv
cruzi
infect
depend
first
consid
possibl
base
geograph
origin
patient
appreci
clinic
pictur
neurolog
sign
present
perform
ct
scan
mri
key
imag
pattern
cn
cruzi
infect
indistinguish
toxoplasm
enceph
direct
microscop
examin
centrifug
sediment
csf
often
show
motil
trypanosom
fever
system
sign
present
direct
examin
buffi
coat
microhematocrit
tube
may
also
show
motil
trypanosom
sinc
serum
antibodi
cruzi
indic
previou
infect
parasit
test
use
rule
reactiv
infect
neg
test
inconclus
biopsi
brain
lesion
demonstr
characterist
organ
done
pcr
blood
csf
requir
research
laboratori
facil
clinic
differenti
hivrel
reactiv
chaga
diseas
chronic
chagas
diseas
may
difficult
hivrel
reactiv
associ
high
parasitemia
howev
wherea
parasitemia
chronic
diseas
low
inde
even
absenc
overt
clinic
reactiv
chronic
chaga
diseas
associ
higher
percentag
level
parasitemia
coinfect
hiv
independ
count
hiv
seroneg
effect
coinfect
appear
bidirect
hiv
viral
load
document
increas
simultan
asymptomat
increas
cruzi
parasitemia
return
baselin
face
success
antiparasit
treatment
nifurtimox
benznidazol
moder
antitrypanosom
activ
standard
drug
recommend
treatment
chaga
diseas
howev
enough
experi
evalu
effect
drug
treatment
cruzi
infect
complic
hivaid
especi
case
meningoenceph
inform
avail
penetr
nifurtimox
benznidazol
cn
surviv
time
report
case
coinfect
short
patient
report
nishioka
cowork
surviv
day
disappear
trypanosom
blood
csf
well
clearanc
brain
lesion
treat
benznidazol
dose
mgkgday
day
clinic
improv
reduct
size
brain
lesion
attribut
treatment
benznidazol
plu
later
itraconazol
fluconazol
anoth
patient
coinfect
surviv
least
month
itraconazol
ketaconazol
use
report
reduc
parasitemia
one
case
case
succumb
hiv
infect
although
report
experi
use
itraconazol
fluconazol
treatment
american
trypanosomiasi
human
itraconazol
report
effect
experiment
infect
recommend
treatment
cruzi
infect
set
hiv
start
earli
reactiv
process
parasitemia
detect
irrevers
endorgan
damag
occur
strategi
would
hing
serolog
identif
risk
someth
indic
hivinfect
individu
appreci
risk
cruzi
infect
although
data
lack
note
immunolog
reconstitut
haart
therapi
like
provid
consider
prophylact
therapeut
benefit
diseas
recombin
antigen
appear
highli
sensit
specif
immunodiagnosi
vl
due
l
donovani
l
chagasi
patient
without
complic
hiv
infect
howev
sensit
immunodiagnosi
cutan
case
turkey
greatli
reduc
compar
case
vl
util
diagnost
clear
hivseroposit
peopl
peripher
parasitemia
display
mani
hivcoinfect
individu
allow
detect
parasit
blood
approxim
case
cultur
polymeras
chain
reaction
pcr
buffycoat
prepar
posit
respect
abund
evid
success
treatment
leishmani
diseas
regardless
drug
use
ultim
requir
intact
cmi
coinfect
patient
victim
doubl
insult
immun
system
vl
associ
antigenspecif
tcell
unrespons
dysfunct
cytokin
respons
situat
compound
immunolog
abnorm
associ
hiv
infect
therapi
vl
face
hiv
coinfect
remain
controversi
larg
due
lack
firm
data
drug
use
treatment
vl
normal
host
includ
pentaval
antimoni
amphotericin
b
prepar
util
treatment
coinfect
patient
albeit
significantli
less
efficaci
amphotericin
b
convent
drug
form
leishmaniasi
includ
viscer
diseas
liposom
encapsul
amphotericin
theoret
advantag
target
macrophag
host
cell
leishmani
parasit
coinfect
patient
initi
parasitolog
cure
treatment
pentaval
antimoni
amphotericin
b
deoxychol
amphotericin
b
lipid
complex
among
option
treatment
lipid
formul
amphotericin
b
appear
similar
efficaci
less
sever
toxic
drug
howev
experi
lipid
formul
amphotericin
b
coinfect
patient
limit
lipid
formul
also
quit
expens
miltefosin
oral
agent
safe
effect
treatment
indian
patient
vl
shown
promis
earli
compassionateus
treatment
vl
hivinfect
subject
even
initi
cure
relaps
predict
occur
coinfect
individu
within
year
optim
drug
secondari
prophylaxi
remain
unclear
pentamidin
given
everi
week
liposomeencapsul
amphotericin
everi
week
week
use
fact
signific
reduct
incid
aidsrel
vl
seen
southern
europ
advent
haart
along
fact
haartrel
immun
reconstitut
allow
secondari
prophylaxi
oi
stop
rais
hope
haart
allow
safe
discontinu
secondari
prophylaxi
vl
american
trypanosomiasi
chaga
diseas
american
trypanosomiasi
see
chapter
wellrecogn
oi
aid
caus
organ
trypanosoma
cruzi
triatomin
vector
wide
distribut
unit
state
chile
argentina
case
hivrel
chaga
diseas
report
date
larg
repres
reactiv
chronic
infect
cours
hivinduc
immunosuppress
primari
infect
face
aid
surpris
given
differ
pattern
epidemiolog
risk
infect
larg
rural
cruzi
larg
urban
hiv
oi
expect
appear
outsid
geograph
bound
note
activ
latent
cruzi
infect
well
exacerb
primari
infect
transmit
blood
transfus
also
well
describ
face
iatrogen
immunosuppress
use
solidorgan
transplant
therapi
hematolog
malign
clinic
cruzi
reactiv
face
hiv
coinfect
appear
occur
larg
tcell
count
less
clinic
reactiv
commonli
involv
central
nervou
system
cn
cruzi
probabl
late
recogn
opportunist
pathogen
set
promin
cook
meat
well
avoid
oocyst
definit
host
cat
avoid
cat
fece
around
dwell
probabl
suffici
oocyst
viabl
month
moist
soil
contamin
fresh
veget
may
common
method
human
infect
foodstuff
probabl
wash
well
cook
primari
prophylaxi
tmpsmx
prefer
taken
toxoplasmaseroposit
hiv
patient
tcell
count
less
safe
discontinu
primari
secondari
prophylaxi
haartrel
immun
reconstitut
sustain
tcell
count
freeliv
ameba
acanthamoeba
balamuthia
genera
see
chapter
rare
caus
opportunist
enceph
cutan
diseas
latestag
aid
case
report
unit
state
worldwid
environment
distribut
ubiquit
protozoan
fact
diagnosi
often
postmortem
suggest
underdiagnosi
widespread
tropic
elsewher
acanthamoeba
balamuthia
isol
soil
water
includ
tap
water
bottl
water
chlorin
pool
natur
sourc
fresh
seawat
air
throughout
world
isol
acanthamoeba
nasopharynx
healthi
adult
indic
organ
may
common
constitu
normal
flora
cellular
immun
along
antibodi
complement
appear
critic
protect
immun
invas
diseas
occur
immunocompromis
debilit
occasion
enceph
balamuthia
mandrillari
occur
appar
normal
host
granulomat
ameb
enceph
gae
subacut
chronic
diseas
compromis
host
caus
multipl
speci
acanthamoeba
well
b
mandrillari
gener
caus
death
week
month
clinic
patholog
data
along
anim
model
suggest
pathogenesi
involv
hematogen
dissemin
brain
initi
respiratori
perhap
cutan
site
infect
patholog
chang
form
necrot
granulomat
inflamm
found
predominantli
posterior
neuraxi
case
gae
due
varieti
speci
report
aid
patient
dissemin
cutan
diseas
subacut
granulomat
dermat
featur
mani
case
preced
clinic
cerebr
involv
week
month
subacut
granulomat
dermat
sole
manifest
invas
diseas
patient
tcell
count
hivinfect
individu
gae
report
less
median
time
present
count
report
histori
reveal
clinic
evid
latestag
aid
aid
patient
gae
mark
rapid
cours
death
day
pauciti
wellform
granuloma
comparison
host
diseas
symptomat
involv
nasopharynx
paranas
sinus
skin
prior
develop
gae
common
aid
patient
cutan
lesion
usual
nodular
subsequ
enlarg
ulcer
metastat
spread
lesion
quit
pleomorph
pustul
plaqu
eschar
cellul
howev
confus
catscratch
diseas
cryptococcosi
sporotrichosi
bacillari
angiomatosi
mycobacteri
infect
vascul
common
present
cerebr
diseas
fever
headach
focal
neurolog
deficit
profound
chang
mental
statu
also
frequent
neuroradiolog
find
mimic
toxoplasm
enceph
multipl
enhanc
mass
lesion
surround
edema
csf
find
quit
variabl
high
index
suspicion
tissu
microbiolog
diagnosi
key
antemortem
identif
gae
wet
mount
csf
occasion
use
perhap
less
use
balamuthia
infect
csf
examin
gener
reveal
lymphocyt
pleocytosi
mild
sever
elev
mgdl
protein
normal
low
glucos
signific
interact
agent
african
trypanosomiasi
see
chapter
hiv
delin
although
tcell
macrophag
respons
thought
import
protect
host
respons
trypanosomiasi
trypanosomiasi
suppress
cellular
immun
respons
biolog
interact
two
plausibl
signific
epidemiolog
associ
trypansoma
brucei
gam
biens
hiv
found
whether
hiv
alter
clinic
cours
either
west
east
african
trypanosomiasi
unclear
anecdot
evid
hiv
may
complic
therapi
west
african
trypanosomiasi
howev
patient
treat
melarsoprol
rural
hospit
congo
hivneg
patient
recov
wherea
hivposit
patient
die
treatment
like
due
treatmentrel
encephalopathi
fourth
fail
respond
therapi
addit
two
genera
leishmania
trypanosoma
known
caus
diseas
human
trypanosomatida
famili
includ
genera
parasit
vertebr
insect
plant
three
report
hivinfect
individu
present
symptom
typic
vl
ultrastructur
isoenzym
andor
kinetoplast
dna
analys
isol
lesion
parasit
indic
respons
organ
actual
belong
one
latter
genera
strong
implic
hivrel
immunosuppress
render
human
vulner
normal
nonpathogen
lower
trypanosomatid
toxoplasma
gondii
ubiquit
parasit
mammal
throughout
world
see
chapter
latent
infect
last
lifetim
host
mainten
latenc
depend
cmi
respons
reactiv
latent
infect
common
increas
immunosuppress
aid
princip
manifest
reactiv
toxoplasm
enceph
thu
common
oi
aid
patient
throughout
world
incid
toxoplasm
enceph
proport
preval
latent
infect
popul
risk
aid
unit
state
rate
latent
infect
vari
pari
rate
acquisit
toxoplasma
infect
agedepend
wide
variat
infect
rate
even
narrow
geograph
area
preval
rate
tropic
vari
measur
commun
fall
broad
middl
rang
unit
state
prior
advent
haart
onethird
toxoplasmaseroposit
aid
patient
develop
toxoplasm
enceph
absenc
prophylaxi
case
patient
less
less
preval
toxoplasm
enceph
aid
patient
tropic
unclear
burden
thought
immens
underdiagnos
autopsi
seri
includ
examin
brain
suggest
diseas
preval
rate
latestag
aid
patient
abidjan
divoir
mexico
citi
kampala
uganda
presumpt
diagnosi
toxoplasm
enceph
base
clinic
present
posit
toxoplasma
serolog
characterist
neuroradiolog
featur
final
clinic
diagnosi
made
base
clinic
radiograph
respons
specif
chemotherapi
less
common
manifest
toxoplasmosi
aid
includ
pneumonia
retinochoroid
myocard
orchiti
gastrointestin
involv
excel
review
toxoplasma
aid
provid
inform
clinic
manag
cosmopolitan
oi
five
percent
toxoplasm
enceph
occur
reactiv
acut
infect
prevent
transmiss
gondii
toxoplasmaseroneg
hivinfect
peopl
two
facet
avoid
ingest
tissu
cyst
intermedi
mammalian
host
ie
approach
patient
hiv
coinfect
tropic
infecti
diseas
report
one
common
parasit
etiolog
agent
diarrhea
hivinfect
individu
rival
rate
cryptosporidium
rate
infect
fallen
dramat
introduct
haart
isosporiasi
usual
present
chronic
wateri
diarrhea
weight
loss
without
vomit
abdomin
pain
fever
invas
gallbladd
tissu
similar
describ
cryptosporidium
describ
along
dissemin
involv
mesenter
tracheobronchi
lymph
node
set
hiv
coinfect
promin
tissu
eosinophilia
involv
lamina
propria
often
present
tmpsmx
provid
effect
therapi
pyrimethamin
leucovorin
provid
second
option
clinic
respons
usual
rapid
relaps
common
absenc
immun
reconstitut
suppress
therapi
indic
cyclospora
cayetanensi
see
chapter
clinic
pictur
enter
infect
c
cayetanensi
aid
appear
similar
due
coccidia
biliari
tract
involv
manifest
right
upperquadr
pain
elev
alkalin
phosphatas
thicken
gallbladd
ultrasound
also
describ
cyclospora
infect
thu
three
human
enter
coccidia
capabl
invad
gallbladd
isosporiasi
cyclosporiasi
aid
treatabl
tmpsmx
followup
suppress
therapi
indic
microsporidiosi
microsporidia
intracellular
protozoan
due
hiv
aid
emerg
rel
obscur
pathogen
insect
fish
laboratori
anim
occupi
new
role
import
oi
human
cosmopolitan
emerg
pathogen
immunosuppress
includ
enterocytozoon
bienusi
e
septata
intestinali
e
cuniculi
e
hellem
well
pathogen
sever
genera
consid
chapter
entamoeba
histolytica
intestin
parasit
see
chapter
initi
associ
hiv
high
preval
men
sex
men
msm
seropreval
studi
continu
indic
high
exposur
rate
msm
although
signific
observ
remain
unclear
despit
consider
evid
immun
amebiasi
requir
particip
cmi
evid
patient
hiv
infect
aid
like
develop
invas
diseas
e
histolytica
high
preval
infect
g
lamblia
see
chapter
found
among
msm
studi
msm
perform
time
reveal
increas
preval
sever
giardiasi
patient
aid
sinc
evid
found
signific
effect
hiv
coinfect
although
studi
indic
higher
preval
giardiasi
hiv
seroposit
consist
find
therapi
giardiasi
peopl
aid
usual
success
patient
immunocompromis
well
immunocompet
refractori
standard
therapeut
regimen
giardiasi
may
well
refractori
standard
therapi
found
commonli
face
hiv
coinfect
controversi
continu
exist
role
organ
caus
diarrheal
diseas
either
immunocompet
patient
hivinfect
peopl
balantidium
coli
inform
avail
whether
organ
serv
oi
hivinfect
peopl
trophozoit
cyst
found
tissu
biopsi
cyst
mistaken
sporangia
rhinosporium
prototheca
cryptococci
trophozoit
mistaken
macrophag
acanthamoeba
isol
cultur
escherichia
coliseed
nonnutri
agar
tissu
cultur
medium
identif
speci
even
differenti
acanthamoeba
balamuthia
possibl
morpholog
immunofluoresc
techniqu
differenti
acanthamoeba
group
level
tissu
section
cultur
organ
treatment
dissemin
diseas
due
organ
difficult
host
chemotherapeut
regimen
clearli
efficaci
miltefosin
show
efficaci
recent
report
case
agent
possibl
clinic
util
combin
therapi
includ
pentamidin
sulfamethazin
sulfadiazin
fluconazol
itraconazol
ketoconazol
macrolid
phenothiazin
rifampin
may
valu
test
clinic
isol
drug
sensit
isol
cerebr
lesion
may
role
surgic
excis
case
primari
ameb
meningoenceph
due
appar
newli
recogn
ameba
associ
thermal
pollut
water
report
patient
latestag
aid
spain
enter
coccidiosi
isospora
cryptosporidium
cyclospora
trio
coccidian
protozoa
isospora
belli
cryptosporidium
spp
cyclospora
eimeria
cayetanensi
promin
caus
selflimit
smallbowel
diarrhea
immunolog
normal
host
well
caus
chronic
sever
diseas
face
hiv
coinfect
cosmopolitan
infect
infect
fourth
organ
sarcocysti
homini
respons
enter
dissemin
coccidioisi
human
report
coinfect
organ
hand
case
hiv
infect
cryptosporidium
spp
see
chapter
addit
common
human
pathogen
within
genu
c
homini
varieti
zoonot
speci
also
infect
human
includ
c
parvum
c
cani
c
feli
c
meleagridi
c
muri
zoonot
speci
may
caus
sever
human
diseas
may
occur
commonli
immunocompromis
peopl
high
preval
diseas
lack
effect
specif
treatment
cryptosporidiosi
particularli
common
sever
problem
oi
throughout
world
chronic
infect
diseas
frequent
tcell
count
less
associ
increas
mortal
use
haart
therapi
led
decreas
preval
cryptosporidi
diseas
hivinfect
individu
howev
rate
diarrhea
hivinfect
individu
associ
cryoptosporidium
spp
develop
countri
remain
high
symptomat
asymptomat
individu
four
clinic
syndrom
cryptosporidi
diarrheal
diseas
patient
aid
limn
chronic
diarrhea
choleralik
diseas
transient
diarrhea
relaps
ill
sever
end
spectrum
seen
larg
tcell
count
less
less
commonli
extraintestin
site
secondarili
involv
includ
biliari
tract
stomach
pancrea
lung
paranas
sinus
middl
ear
biliari
tract
involv
present
right
upperquadr
pain
nausea
vomit
fever
repres
common
clinic
import
site
found
onefourth
patient
aidsrel
intestin
diseas
prior
use
haart
individu
tcell
count
less
particular
risk
develop
symptomat
biliari
diseas
antimicrobi
agent
demonstr
consist
efficaci
hivrel
cryptosporidiosi
immun
reconstitut
haart
pursu
along
support
treatment
fluid
nutrit
antimotil
agent
isospora
belli
see
chapter
diseas
due
isospora
less
cosmopolitan
due
cryptosporidium
common
tropic
subtrop
area
region
unclear
latter
interpret
favor
previou
similar
case
report
presum
dissemin
cestod
infect
face
immunosuppress
due
hodgkin
diseas
therapi
four
case
exuber
subcutan
diseas
due
larval
form
taenia
crassicep
report
aid
patient
thu
hiv
infect
may
risk
diseas
cestod
case
hepat
alveolar
echinococc
diseas
child
aid
describ
uncommon
featur
case
includ
remark
young
age
henc
short
incub
period
diseas
complet
lack
demonstr
parasitespecif
humor
cellular
immun
respons
pauciti
report
case
hydatid
diseas
hivinfect
patient
permit
conclus
biolog
clinic
cours
coinfect
final
sever
case
neurocysticercosi
report
hivinfect
patient
case
coinfect
present
multipl
parenchym
lesion
frequenc
giant
cyst
racemos
form
diseas
elev
report
case
perhap
reflect
role
cell
tissu
immun
solium
clinic
data
interact
hiv
cestod
infect
await
strongyloid
stercorali
see
chapter
appear
qualifi
potenti
oi
one
two
nematod
apart
capillaria
philip
pinensi
coinfect
yet
report
capabl
multipli
human
host
especi
immunocompromis
subject
one
way
immunosuppress
enhanc
strongyloid
infect
permit
stimul
increas
degre
normal
process
autoinfect
process
firststag
rhabditiform
larva
produc
adult
femal
worm
upper
small
bowel
transform
infect
filariform
larva
reinvad
colon
intestin
wall
perian
perin
area
massiv
upregul
autoinfect
process
result
hyperinfect
syndrom
develop
mani
adult
worm
product
larg
number
larva
dissemin
organ
clinic
pictur
domin
gramneg
bacteri
sepsi
mening
andor
pneumonia
hyperinfect
usual
associ
immunosuppress
particularli
administr
corticosteroid
strongyloidiasi
initi
design
aid
oi
base
past
record
stercorali
caus
hyperinfect
immunosuppress
five
year
later
becam
appar
hyperinfect
syndrom
encount
frequent
patient
aid
remov
list
aidsdefin
oi
given
low
appreci
rate
strongyloidiasi
among
men
attend
sexual
transmit
diseas
clinic
new
york
citi
aid
epidem
unit
state
provid
clinic
evid
predisposit
aid
patient
hyperinfect
occur
avail
evid
make
extrem
unlik
misdiagnosi
underreport
relev
factor
sever
strongyloidiasi
hyperinfect
syndrom
promin
clinic
featur
often
fatal
untreat
like
associ
would
escap
notic
case
hyperinfect
syndrom
report
englishlanguag
literatur
even
among
case
presenc
hyperinfect
poorli
document
mani
frequent
confus
sever
gi
diseas
hyperinfect
diagnosi
oppos
suspicion
hyperinfect
syndrom
depend
demonstr
markedli
increas
number
filariform
larva
stool
multipl
larva
sputum
mere
presenc
filariform
larva
sputum
indic
exist
autoinfect
also
note
presenc
rhabditiform
larva
sputum
point
neither
autoinfect
hyperinfect
presenc
adult
femal
worm
lung
possibl
frequenc
sever
strongyloidiasi
complic
hiv
infect
much
higher
certain
area
tropic
infect
preval
medic
facil
lack
howev
evid
trematod
infect
sever
difficult
treat
face
hiv
coinfect
subtl
interact
explor
schistosomiasi
see
chapter
studi
car
washer
work
shore
lake
victoria
kenya
popul
high
intens
exposur
schistosoma
mansoni
hiv
seropreval
approxim
provid
insight
bidirect
effect
coinfect
tcelldepend
granulomat
respons
schistosom
egg
shown
import
egg
migrat
venul
lumen
intestin
mous
model
diseas
might
therebi
expect
signific
suppress
egg
excret
effici
control
degre
infect
found
mansoniinfect
patient
presenc
hiv
coinfect
low
tcell
count
although
success
therapi
mansoni
infect
praziquantel
may
depend
host
antibodi
respons
praziquantel
efficaci
treat
schistosomiasi
hivinfect
cohort
given
schistosom
infect
like
preced
hiv
infect
individu
whether
praziquantel
equal
efficaci
individu
infect
first
hiv
remain
open
question
context
studi
kenya
report
treatment
standard
regimen
praziquantel
coinfect
individu
result
normal
kinet
reduct
egg
excret
slower
declin
serum
level
adult
worm
antigen
interpret
indic
less
effici
kill
adult
worm
notabl
despit
similar
respons
therapi
individu
hiv
coinfect
low
tcell
count
show
increas
suscept
reinfect
therapi
someth
appear
correl
blunt
immunolog
respons
success
drug
therapi
result
releas
parasit
antigen
individu
studi
hiv
haematobium
coinfect
zambia
mirror
find
coinfect
individu
lower
egg
excret
praziquantel
retain
efficaci
face
coinfect
alter
resist
reinfect
haematobium
seen
face
hiv
infect
tcell
count
perform
cohort
lack
clinic
evid
hiv
diseas
thu
remain
possibl
mansoni
infect
resist
reinfect
haematobium
decreas
progress
hivaid
effect
schistosomiasi
hiv
femal
male
urogenit
schistosomiasi
like
inflammatori
genit
diseas
thought
increas
risk
hiv
transmiss
schistosomiasi
also
prime
exampl
chronic
tropic
infect
postul
enhanc
pathogenesi
hiv
schistosom
infect
act
power
induc
polar
immun
counterregulatori
respons
mice
human
infect
also
like
alter
gut
mucos
permeabl
system
exposur
gutderiv
microbi
product
note
follow
heel
neg
studi
recent
random
trial
praziquantel
schistosomiasi
found
signific
benefit
treatment
plasma
rna
load
along
nonsignific
trend
toward
benefici
effect
count
hivinfect
individu
literatur
appear
silent
whether
signific
interact
pulmonari
hepat
intestin
trematod
hiv
unusu
manifest
cestod
infect
report
aid
patient
rapidli
expand
invas
ultim
lethal
abdomin
mass
patient
tcell
count
less
found
ribosom
dna
amplif
sequenc
due
hymenolepi
nana
whether
repres
mere
fortuit
concurr
unusu
patholog
find
dramat
improv
diagnost
technolog
previou
rare
case
normal
host
occur
absenc
diagnosi
recognit
new
diseas
express
facilit
depend
immunosuppress
aid
patient
serv
sentinel
chicken
popul
larg
approach
patient
hiv
coinfect
tropic
infecti
diseas
two
infect
differ
efficaci
ivermectin
treatment
hivinfect
compar
uninfect
patient
onchocerc
skin
diseas
may
wors
face
hiv
infect
hivcoinfect
individu
lower
level
antibodi
volvulu
contrast
two
studi
suggest
signific
epidemiolog
associ
lymphat
filariasi
see
chapter
hiv
infect
increas
infect
cell
may
underli
surpris
find
although
similarli
increas
risk
hiv
infect
observ
infect
helminth
effect
lymphat
filariasi
hiv
progress
random
doubleblind
placebocontrol
crossov
trial
diethylcarbamazin
wuchereria
bancrofti
infect
report
signific
treatmentassoci
decreas
plasma
rna
load
along
nonsignific
trend
toward
benefici
effect
count
arthropod
sarcopt
scabiei
var
homini
stand
alon
among
arthropod
crustacean
infest
human
see
chapter
caus
exacerb
diseas
presenc
hiv
normal
host
scabi
usual
manifest
markedli
prurit
papular
vesicular
dermat
pathognomon
burrow
harbor
gravid
femal
excori
nodul
eczemat
impetigin
plaqu
may
also
found
rel
adult
mite
normal
present
crust
scabi
seen
neurolog
impair
immunosuppress
patient
pruritu
often
absent
mild
lesion
consist
widespread
hyperkeratot
crust
scale
fissur
plaqu
nail
frequent
involv
patient
tend
heavili
infest
thousand
adult
mite
see
chapter
crust
scabi
report
complic
hiv
infect
tcell
count
report
case
less
typic
atyp
present
seen
latter
includ
pruritu
aid
crust
pruritu
prurit
papular
dermat
mimic
darier
diseas
psoriasi
secondari
sepsi
death
report
face
clinic
variabl
diagnosi
crust
scabi
hivseroposit
peopl
rest
appropri
clinic
suspicion
demonstr
heavi
infest
microscop
examin
skin
scrape
extraordinari
mite
load
patient
remark
contagi
combin
therapi
ivermectin
topic
benzyl
benzoat
perhap
permethrin
appear
treatment
choic
singledos
ivermectin
also
effect
prevent
transmiss
close
contact
evid
transmiss
hiv
arthropod
vector
prurit
papular
erupt
associ
hiv
infect
common
subsaharan
africa
etiolog
intens
prurit
lesion
attribut
exagger
immun
respons
arthropod
bite
hivinfect
individu
dissemin
infect
p
marneffei
dimorph
fungu
endem
southeast
asia
southern
china
see
chapter
emerg
import
oi
aid
patient
third
common
oi
hiv
diseas
northern
thailand
extrapulmonari
tuberculosi
cryptococc
mening
infect
p
marneffei
rare
event
arriv
aid
pandem
sinc
thousand
case
diagnos
primarili
southern
china
northern
thailand
hong
kong
taiwan
malaysia
vietnam
singapor
indonesia
myanmar
overwhelm
major
case
aid
patient
although
normal
host
also
known
develop
system
diseas
fungu
pronounc
intracountri
variat
infect
rate
northern
thailand
onefourth
aid
patient
suffer
diseas
wherea
southern
thailand
preval
less
remain
unresolv
whether
human
diseas
penicilliosi
result
zoonot
sapronot
transmiss
ecolog
reservoir
remain
unknown
despit
decad
absenc
associ
note
area
petithori
derouin
point
clinic
studi
aid
patient
central
africa
preval
strongyloidiasi
vari
mention
extraintestin
strongyloidiasi
similarli
report
brazil
estim
preval
strongyloid
infect
popul
paulo
find
parasit
aid
patient
show
evid
system
strongyloidiasi
similar
result
found
zambia
survey
urban
adult
kinshasa
detect
stercorali
intens
fecal
examin
singl
specimen
estim
infect
rate
popul
basi
posit
serolog
signific
differ
infect
rate
seroposit
seroneg
hiv
f
neva
unpublish
observ
taken
togeth
data
suggest
presenc
sever
clinic
diseas
due
stercorali
significantli
increas
patient
hiv
infect
aid
alon
recent
studi
shed
light
subject
care
quantit
number
proport
freeliv
adult
worm
directli
develop
larva
stool
cultur
reveal
surpris
neg
correl
tcell
count
develop
infecti
larva
gut
latter
process
necessari
autoinfect
subtl
interact
increas
mean
gi
parasit
burden
slower
respons
therapi
may
miss
also
condit
cosegreg
hivaid
known
predispos
hyperinfect
syndrom
includ
use
steroid
given
pneumocysti
pneumonia
lymphoma
aid
inanit
seen
patient
chronic
diarrhea
untreat
oropharyng
esophag
candidiasi
slim
diseas
coinfect
human
tcell
lymphotrop
viru
type
htlvi
see
chapter
strongyloidiasi
import
oi
individu
infect
htlvi
strongyloid
infect
suspect
cofactor
develop
acut
tcell
leukemia
tropic
spastic
paraparesi
asymptomat
carrier
htlvi
notabl
intraven
drug
use
risk
factor
infect
htlvi
hiv
approxim
onethird
onehalf
world
popul
thought
infect
soiltransmit
geohelminth
apart
stercorali
heaviest
public
health
burden
pose
ascari
lumbri
coid
hookworm
speci
trichuri
trichuria
publish
data
indic
infect
diseas
latter
organ
excerb
hiv
infect
inde
case
hookworm
anemia
independ
risk
factor
earli
death
hiv
hookworm
infect
lead
anemia
actual
literatur
hookworm
infect
hiv
reveal
anyth
strike
apart
puzzl
find
neg
associ
hookworm
infect
hiv
infect
significantli
higher
cell
count
hivinfect
individu
hookworm
infect
without
hookworm
infect
significantli
lower
preval
mean
intens
hookworm
infect
pulmonari
tuberculosi
hiv
pulmonari
tuberculosi
without
hiv
signific
observ
remain
unclear
hand
reason
discuss
chronicrecurr
geohelminth
infect
suspect
cofactor
hiv
progress
follow
public
conflict
studi
recent
random
doubleblind
placebocontrol
trial
albendazol
infect
divers
geohelminth
includ
hookworm
ascari
trichuri
found
signific
benefit
treatment
tcell
count
specif
face
ascari
infect
consider
preval
hookworm
infect
nonsignific
trend
toward
benefici
effect
treatment
plasma
rna
load
also
seen
data
need
subject
among
tissueinfect
filaria
effect
hiv
coinfect
studi
larg
cohort
patient
onchocerca
volvulu
infect
see
chapter
signific
epidemiolog
associ
found
capsulatum
c
neoforman
tissu
characterist
intracellular
organ
detect
routin
blood
smear
seri
discuss
definit
diagnosi
perform
cultur
p
marneffei
blood
even
absenc
routin
lysiscentrifug
cultur
skin
biopsi
bone
marrow
sputum
diagnost
antigenemia
test
may
prove
valuabl
rapid
diagnosi
develop
quantit
urinari
antigen
enzym
immunoassay
especi
promis
high
sensit
specif
demonstr
area
high
endemn
note
p
marneffei
infect
known
caus
falseposit
reaction
h
capsulatum
polysaccharid
antigen
immunoassay
also
crossreact
antisera
rais
aspergillu
galactomannan
current
serolog
assay
unlik
help
diagnosi
aid
patient
improv
sensit
may
provid
use
index
infect
amphotericin
b
mgkgday
week
follow
itraconazol
mg
twice
day
week
safe
effect
mild
moder
ill
patient
primari
therapi
itraconazol
may
reason
voriconazol
also
shown
success
treatment
p
marnef
fei
infect
hivinfect
travel
nonendem
region
secondari
prophylaxi
mandatori
given
relaps
rate
within
month
absenc
placebocontrol
doubleblind
random
trial
show
secondari
prophylaxi
itraconazol
mg
daili
safe
effect
immun
reconstitut
result
success
respons
haart
discontinu
secondari
prophylaxi
probabl
safe
control
doubleblind
trial
primari
prophylaxi
itraconazol
mg
daili
thai
patient
aid
tcell
count
less
show
regimen
well
toler
effect
prevent
cryptococcosi
penicilliosi
surviv
benefit
found
studi
power
detect
surviv
advantag
dimorph
fungu
p
brasiliensi
caus
common
system
mycosi
latin
america
see
chapter
two
clinic
form
distinguish
normal
host
acut
subacut
juvenil
form
chronic
adult
form
acut
juvenil
diseas
occur
children
young
adult
account
small
minor
case
mark
rapid
cours
dissemin
involv
macrophag
lymphoid
tissu
sever
suppress
cmi
chronic
adult
diseas
account
vast
major
case
slowli
progress
diseas
predominantli
older
men
patient
primari
clinic
patholog
manifest
pulmonari
nodular
infiltr
cavitari
lesion
progress
fibrosi
frequent
manifest
adult
diseas
includ
infiltr
ulcer
mucos
lesion
oroand
nasopharynx
polymorph
cutan
lesion
lymphadenopathi
adren
infiltr
infect
subclin
long
latenc
clearli
demonstr
mean
year
leav
endem
area
present
thought
cmi
respons
critic
host
defens
diseas
p
brasiliensi
clinic
experiment
evid
indic
paracoccidioidomycosi
associ
mark
abnorm
immun
function
suppress
cmi
respons
polyclon
bcell
activ
elev
plasma
ige
level
immunolog
perturb
common
sever
juvenil
diseas
revers
success
therapi
given
immunolog
paracoccidioidomycosi
one
might
expect
promin
oi
south
america
among
hiv
patient
histori
travel
fact
fewer
case
report
despit
presum
wide
preval
infect
coinfect
area
urban
brazil
possibl
reason
low
number
case
hivseroposit
patient
includ
prophylaxi
tmpsmx
activ
p
brasiliensi
use
ketoconazol
oropharyng
candidiasi
misdiagnosi
pneumocysti
carinii
pneumonia
therapeut
respons
tmpsmx
lack
diagnosi
presenc
particularli
subtl
interact
hiv
paracoccidioid
brasiliensi
research
organ
isol
organ
fece
burrow
three
speci
bamboo
rat
geograph
rang
rodent
overlap
previous
mention
known
area
endem
diseas
p
marneffei
suggest
likelihood
fungu
also
endem
lao
cambodia
malaysia
whether
bamboo
rat
import
reservoir
human
infect
anoth
natur
host
unclear
evid
transmiss
rat
human
season
distribut
diagnosi
dissemin
diseas
aid
patient
suggest
expans
reservoir
raini
season
exposur
soil
appear
key
factor
pathogenesi
penicilliosi
presum
analog
endem
system
mycos
involv
transmiss
inhal
secondari
system
dissemin
like
histoplasma
capsulatum
p
marnef
fei
intracellular
parasit
macrophag
mous
model
indic
cell
play
central
role
control
infect
coinfect
patient
dissemin
diseas
associ
tcell
count
less
largest
clinic
seri
dissemin
p
marneffei
infect
report
date
provid
detail
inform
patient
symptom
onset
gener
sudden
intens
common
present
symptom
sign
fever
anemia
weight
loss
skin
lesion
similar
pattern
clinic
symptom
also
report
endem
region
frequent
sign
symptom
includ
cough
gener
lymphadenopathi
hepatomegali
diarrhea
common
cutan
manifest
gener
papular
rash
central
umbil
resembl
lesion
molluscum
contagiosum
predominantli
found
face
scalp
upper
extrem
occur
throughout
bodi
includ
palat
cutan
lesion
includ
papul
without
umbil
maculopapular
rash
subcutan
nodul
acnelik
lesion
follicul
chest
film
frequent
abnorm
diffus
reticulonodular
local
alveolar
infiltr
common
mean
durat
ill
prior
present
studi
week
incub
period
dissemin
diseas
unclear
percentag
patient
whose
diseas
result
reactiv
latent
infect
oppos
new
infect
reinfect
fact
reactiv
increas
immunosuppress
occur
support
sever
case
dissemin
diseas
report
nonendem
area
patient
distant
histori
travel
endem
area
mani
patient
spent
littl
time
endem
area
indic
infect
p
marneffei
occur
rapidli
develop
clinic
activ
diseas
within
week
exposur
endem
area
report
children
vertic
transmit
hiv
infect
develop
diseas
first
month
year
life
demonstr
primari
infect
quickli
lead
dissemin
diseas
final
pronounc
season
variat
diseas
incid
impli
import
role
exogen
reinfect
express
diseas
endem
area
mortal
rate
patient
dissemin
p
marneffei
infect
high
absenc
prompt
treatment
diagnosi
depend
high
index
suspicion
includ
care
histori
assess
resid
travel
endem
area
differenti
diagnosi
includ
tuberculosi
endem
fungi
cryptococcosi
cutan
lesion
may
mimic
aidsrel
molluscum
contagiosum
h
capsulatum
cryptococcu
neoforman
absenc
cutan
lesion
may
retard
diagnosi
regard
characterist
syndrom
hepat
diseas
absenc
skin
lesion
fever
hepatomegali
markedli
elev
serum
alkalin
phosphatas
level
note
presumpt
diagnosi
made
examin
wrightsstain
bone
marrow
aspir
lymph
node
aspir
touch
prepar
skin
biopsi
specimen
intracellular
extracellular
basophil
ellipt
yeastlik
organ
central
septat
oppos
bud
h
capsulatum
characterist
p
marneffei
characterist
crosswal
format
within
macrophag
appear
transvers
cell
wall
separ
individu
conidia
help
distinguish
conidioform
fungi
indirect
fluoresc
antibodi
reagent
develop
may
prove
use
differenti
p
marneffei
h
approach
patient
hiv
coinfect
tropic
infecti
diseas
asia
suggest
high
preval
rate
well
cutan
lymphocutan
diseas
common
extracutan
involv
includ
osteoarticular
diseas
pneumonia
mening
describ
normal
immunosuppress
host
hand
case
sever
dissemin
sporotrichosi
latestag
aid
describ
diffus
cutan
involv
norm
patient
also
present
cn
ocular
osteoarticular
splenic
bone
marrow
andor
mucos
involv
appear
like
dissemin
sporothrix
becom
promin
oi
heavili
endem
area
respons
therapi
amphotericin
b
potassium
iodid
itraconazol
ketoconazol
variabl
problemat
amphotericin
b
probabl
use
initi
treatment
follow
lifelong
suppress
therapi
itraconazol
h
capsulatum
blastomyc
dermatitidi
coccidioid
immiti
system
mycos
endem
unit
state
caus
aidsrel
oi
distinctli
tropic
diseas
cover
depth
elsewher
tropic
extent
respect
area
endem
deserv
brief
mention
howev
h
capsulatum
var
capsulatum
see
chapter
found
distinct
river
basin
system
worldwid
equat
progress
dissemin
histoplasmosi
common
aid
patient
endem
area
addit
promin
worldwid
focu
ohio
mississippi
river
valley
unit
state
case
report
central
south
america
caribbean
africa
southeast
asia
europ
diseas
caus
b
dermatitidi
origin
name
north
american
blastomycosi
clear
howev
distribut
fungu
far
cosmopolitan
see
chapter
blastomycosi
report
major
region
africa
concentr
southern
africa
like
underreport
occasion
case
report
central
south
america
middl
east
india
african
strain
b
dermatitidi
appear
antigen
distinct
north
american
strain
clinic
spectrum
likewis
appear
differ
african
case
promin
involv
bone
chronic
drain
sinus
dissemin
blastomycosi
uncommon
late
frequent
fatal
oi
patient
aid
unit
state
case
africa
expect
futur
c
immiti
endem
lower
sonoran
life
zone
unit
state
mexico
guatemala
hondura
colombia
venezuela
bolivia
paraguay
argentina
see
chapter
coccidioidomycosi
sever
often
fatal
diseas
patient
aid
low
tcell
count
present
diffus
focal
pulmonari
diseas
extrapulmonari
dissemin
uncommon
endem
area
third
common
oi
aid
patient
cryptococcu
neoforman
cryptococcosi
see
chapter
common
lifethreaten
fungal
infect
aid
patient
although
c
neoforman
dissemin
organ
system
face
hiv
infect
mening
frequent
manifest
rel
common
manifest
includ
pneumonia
cutan
lesion
occur
commonli
count
fall
well
cryptococcosi
frequent
present
diagnosi
aid
excel
review
cryptococcosi
aid
avail
detail
inform
clinic
approach
ubiquit
oi
c
neoforman
distribut
global
distribut
cryptococcu
oi
aid
global
well
region
differ
exist
preval
diseas
defin
clinic
autopsi
seri
preval
cryptococcosi
aid
patient
unit
state
estim
thailand
second
common
oi
tuberculosi
preval
differ
clinic
seri
africa
case
seri
preval
variabl
soweto
south
africa
kinshasa
former
zair
preval
autopsi
seri
similarli
vari
paracoccidioidomycosi
hivseroposit
peopl
primarili
acut
form
howev
pulmonari
oral
mucos
involv
typic
chronic
form
often
coexist
although
publish
report
suggest
dissemin
diseas
may
occur
across
broad
rang
hivassoci
immunosuppress
tcell
count
less
report
norm
onethird
patient
paracoccidioidomycosi
present
anoth
opportunist
coinfect
frequent
oralesophag
candidiasi
tuberculosi
report
clinic
present
span
wide
spectrum
rel
indol
rapidli
progress
diseas
clinic
manifest
includ
prolong
fever
weight
loss
cough
dyspnea
gener
lymphadenopathi
hepatosplenomegali
skin
lesion
local
dissemin
maculopapular
nodular
ulcer
oral
lesion
ulcer
andor
nodular
osteoarticular
lesion
mening
diagnosi
patient
made
direct
examin
cultur
clinic
specimen
includ
skin
biopsi
lymph
node
aspir
biopsi
bone
marrow
aspir
csf
blood
sputum
also
examin
use
potassium
hydroxid
prepar
calcofluor
stain
immunofluoresc
pilot
wheel
cell
consist
numer
small
bud
surround
mother
cell
characterist
serolog
diagnost
help
pcr
use
primer
region
ribosom
gene
found
highli
sensit
specif
test
may
prove
use
diagnost
tool
near
futur
mortal
report
case
diseas
hivseroposit
peopl
random
clinic
trial
perform
drug
commonli
use
treatment
p
brasiliensi
infect
sulfonamid
amphotericin
b
ketoconazol
itraconazol
even
normal
host
treatment
recommend
base
data
case
seri
comparison
histor
control
howev
data
fairli
compel
itraconazol
mgday
drug
choic
normal
host
howev
increas
incid
african
histoplasmosi
report
studi
peopl
republ
congo
congo
republ
despit
rapid
increas
aidsrel
incid
cryptococc
diseas
diseas
manifest
report
report
coinfect
suggest
aid
patient
risk
sever
dissemin
diseas
diagnosi
typic
direct
examin
clinic
specimen
cultur
serodiagnost
test
crossreact
aspergillu
penicillium
yeast
form
larger
thicker
wall
h
capsulatum
var
capsulatum
amphotericin
b
itraconazol
therapeut
efficaci
advent
haart
increas
concern
emerg
histoplasma
invas
fungi
caus
iri
dimorph
fungu
schenckii
worldwid
distribut
although
report
tropic
subtrop
area
america
see
chapter
highest
incid
diseas
thought
highland
mexico
southern
brazil
recent
report
south
predominantli
tropic
fungi
agent
maduromycosi
lobomycosi
rhinosporidiosi
subcutan
zygomycosi
may
prove
caus
oi
aid
patient
appear
report
isol
case
report
infect
due
varieti
unusu
fungi
aid
patient
publish
review
refer
may
inde
prove
oi
even
predominantli
tropic
oi
firm
data
lack
common
occurr
superfici
invas
infect
candida
grow
problem
aspergillu
infect
neutropen
longterm
survivor
latestag
aid
beyond
scope
chapter
approxim
onethird
live
hiv
worldwid
coinfect
tuberculosi
see
chapter
develop
countri
patient
hiv
infect
develop
activ
tb
contrast
unit
state
patient
aid
tb
countri
subsaharan
africa
tb
patient
hivseroposit
tb
lead
caus
death
among
peopl
hiv
infect
account
onethird
aid
death
worldwid
introduct
haart
decreas
death
oi
tb
among
peopl
live
hiv
worldwid
affluent
countri
develop
countri
howev
haart
still
remain
avail
minor
need
avium
complex
mac
see
chapter
consist
multipl
serovar
two
mycobacterium
speci
avium
intracellular
mac
bacteria
ubiquit
organ
commonli
isol
soil
natur
sourc
water
tap
water
domest
wild
anim
worldwid
mac
isol
aid
patient
avium
serovar
dissemin
diseas
due
avium
common
system
bacteri
infect
aid
patient
industri
north
occur
aid
patient
unit
state
diseas
occur
almost
exclus
tcell
count
less
frequent
tcell
count
less
pathogenesi
dissemin
avium
infect
aid
thought
involv
primari
infect
reinfect
oppos
reactiv
initi
colon
respiratori
gi
tract
follow
widespread
dissemin
system
diseas
mark
highgrad
mycobacteremia
almost
exclus
monocyt
impress
tissu
burden
bacteria
remark
featur
avium
tropic
appar
virtual
absenc
dissemin
diseas
aid
patient
mani
area
predominantli
subsaharan
africa
none
blood
cultur
sever
ill
patient
advanc
aid
uganda
posit
avium
mycobacteri
sputum
cultur
hivseroposit
seroneg
patient
hospit
found
posit
avium
overal
rate
diseas
africa
appear
higher
north
america
europ
interestingli
larg
retrospect
case
studi
london
found
significantli
higher
rate
extrapulmonari
cryptococc
diseas
african
attend
hiv
clinic
nonafrican
attend
clinic
data
case
seri
estim
preval
cryptococcosi
mexico
haiti
brazil
patient
cryptococcu
aidsdefin
diagnosi
cryptococc
infect
estim
contribut
aidrel
death
develop
countri
c
neoforman
exist
two
varieti
c
neoforman
var
neoforman
c
neoforman
var
gatti
inhabit
differ
ecolog
nich
c
neoforman
var
neoforman
associ
soil
contamin
bird
excrement
c
neoforman
var
gatti
uniqu
poorli
understood
associ
tree
eucalyptu
camaldulensi
complet
genom
sequenc
c
neoforman
enough
differ
found
sequenc
two
fungal
subspeci
propos
rais
c
neoforman
gatti
speci
c
gatti
wherea
c
gatti
predominantli
tropic
subtrop
distribut
c
neo
forman
occur
worldwid
note
although
cryptococcosi
due
c
gatti
occur
regular
normal
host
region
varieti
endem
case
cryptococcosi
aid
patient
almost
exclus
due
c
neoforman
pneumocysti
jirovecii
throughout
world
almost
univers
serolog
evid
exposur
age
year
p
jirovecii
see
chapter
preval
antibodi
specif
p
jirovecii
antigen
vari
howev
suggest
exposur
antigen
differ
strain
differ
area
world
mirror
genet
studi
reveal
strain
differ
organ
prior
haart
pcp
pneumocysti
carinii
pneumonia
base
prior
terminolog
occur
patient
unit
state
europ
count
less
per
year
patient
overal
absenc
prophylaxi
pcp
preval
appear
high
among
aid
patient
central
south
america
asia
interestingli
howev
incid
pcp
adult
aid
patient
africa
may
far
lower
seen
prehaart
era
industri
countri
adult
clinic
seri
africa
shown
preval
rate
studi
includ
bronchoscopi
diagnosi
describ
rate
highest
figur
obtain
percentag
acidfast
bacillusneg
pneumonia
autopsi
seri
rate
reason
lower
rate
unclear
possibl
explan
includ
less
environment
exposur
exposur
differ
strain
differ
host
suscept
earlier
death
tropic
patient
aid
due
exposur
virul
organ
diagnost
difficulti
hostspecif
differ
suscept
exist
genet
antigen
distinct
human
strain
like
howev
pediatr
pcp
rate
aid
patient
africa
quit
similar
industri
north
inde
approxim
onethird
hivinfect
infant
africa
die
first
year
life
pcp
thought
respons
death
demis
virul
pathogen
prior
clinic
pcp
may
well
occur
adult
pcp
tend
occur
earli
cours
hiv
diseas
north
american
infant
perhap
initi
exposur
high
preval
cryptococc
diseas
seri
thought
occur
similar
level
immunosuppress
suggest
complet
answer
recent
studi
africa
use
bronchoscopi
improv
microbiolog
identif
yield
higher
rate
pcp
possibl
lower
rate
earlier
studi
may
repres
report
bia
introduc
use
suboptim
diagnost
techniqu
clinic
present
pcp
tropic
appear
similar
industri
north
frequent
coinfect
tuberculosi
may
obscur
diagnosi
multipl
review
clinic
approach
pcp
aid
avail
approach
patient
hiv
coinfect
tropic
infecti
diseas
among
new
case
leprosi
match
age
sex
district
resid
control
uganda
signific
differ
overal
posit
rate
found
case
versu
control
posit
hiv
reaction
frequent
among
multibacillari
case
differ
clinic
associ
note
zambia
leprosi
patient
activ
neuriti
suggest
hivposit
case
poorer
recoveri
nerv
function
control
treatment
steroid
factor
consid
evalu
report
hivaid
leprosi
patient
greater
likelihood
falseposit
serolog
reaction
one
posit
band
hiv
antigen
western
blot
commonli
found
sever
hundr
sera
northern
india
absenc
posit
enzymelink
immunosorb
assay
elisa
anoth
report
claim
sera
indonesia
sera
somalia
gave
posit
hiv
elisa
neg
western
blot
attribut
leprosi
publish
epidemiolog
data
show
neither
increas
hiv
preval
among
leprosi
case
higher
rate
hiv
among
individu
infect
lepra
appear
strike
evid
hiv
infect
advers
effect
cours
leprosi
clear
alter
clinic
spectrum
leprosi
among
coinfect
patient
although
suggest
immunemedi
reaction
complic
leprosi
occur
higher
frequenc
coinfect
patient
sever
report
suggest
possibl
multibacillari
diseas
may
develop
readili
coinfect
howev
sever
featur
leprosi
may
tend
obscur
interact
hiv
infect
infect
chronic
slow
progress
may
simpli
take
time
recogn
influenc
one
leprosi
predominantli
rural
infect
hivaid
urban
patient
aid
tropic
may
surviv
long
enough
display
interact
leprosi
final
patient
earli
stage
leprosi
rel
subtl
clinic
manifest
physician
urban
environ
may
familiar
therefor
may
go
realiz
leprosi
report
present
immun
reconstitut
diseas
among
patient
commenc
haart
diseas
due
genavens
see
chapter
mimic
due
avium
caus
dissemin
diseas
aid
patient
low
tcell
count
mean
pathogenesi
appear
involv
initi
gi
colon
follow
dissemin
import
environment
reservoir
unclear
pet
bird
extens
gi
tract
involv
organ
may
also
present
tap
water
geograph
rang
diseas
begin
defin
case
report
north
america
europ
australia
common
present
symptom
sign
fever
weight
loss
abdomin
pain
chronic
diarrhea
lymphadenopathi
hepatosplenomegali
pseudowhippl
diseas
anemia
imag
spleen
may
suggest
splenic
abscess
diffus
nodular
infiltr
may
seen
lung
patholog
involv
organ
fill
histiocyt
pack
acidfast
bacilli
diagnosi
establish
isol
genavens
normal
steril
site
blood
bone
marrow
lymph
node
spleen
specif
diagnosi
confound
fastidi
growth
requir
organ
primari
isol
solid
media
difficult
growth
liquid
broth
may
sensit
definit
identif
demand
pcr
techniqu
clear
implic
signific
percentag
case
ascrib
dissemin
avium
like
due
genavens
data
treatment
retrospect
therapi
appear
associ
improv
symptom
surviv
multidrug
regimen
includ
clarithromycin
appear
associ
best
clinic
respons
like
nontubercul
mycobacteria
genovens
also
report
declar
iri
aid
pandem
kansasii
known
primarili
caus
chronic
pulmonari
diseas
resembl
tb
lung
diseas
due
avium
wherea
hospit
patient
aid
brazil
avium
cultur
bone
marrow
data
avail
india
southeast
asia
one
studi
east
asia
show
pattern
mac
infect
similar
seen
west
mycobacteremia
identifi
due
mac
reason
appar
absenc
dissemin
diseas
due
avium
area
tropic
unclear
decreas
preval
pcp
mani
explan
propos
includ
less
exposur
exposur
less
pathogen
variant
differ
host
suscept
greater
acquir
immun
mycobacteria
earlier
death
virul
pathogen
diagnost
difficulti
overal
exposur
mac
organ
like
similar
environment
isol
mac
occur
similar
greater
frequenc
congo
uganda
unit
state
skin
test
survey
suggest
similar
frequenc
exposur
mac
econom
develop
develop
countri
pipe
water
system
unit
state
europ
higher
frequenc
mac
isol
howev
econom
condit
may
lead
greater
exposur
maccontain
droplet
via
showerhead
econom
develop
countri
differ
howev
unlik
lead
essenti
total
absenc
diseas
countri
uganda
exposur
differ
avium
serovar
strain
may
well
import
data
serotyp
african
clinic
strain
scarc
preliminari
data
suggest
african
clinic
isol
distinguish
european
american
isol
restrict
fragment
length
polymorph
analysi
possibl
underli
genet
differ
host
suscept
beli
similar
rate
dissemin
avium
infect
present
diagnosi
african
nonafrican
aid
patient
london
clinic
greater
acquir
immun
mycobacteri
diseas
bacil
bcg
vaccin
prior
infect
tuberculosi
may
exist
report
bcg
coverag
purifi
protein
deriv
ppd
reactiv
uganda
seem
unlik
explain
lack
dissemin
mac
diseas
earlier
death
due
greater
environment
presenc
greater
latent
infect
virul
pathogen
may
occur
unlik
entir
explan
patient
mani
previous
mention
studi
clinic
latestag
aid
final
design
sever
previou
studi
make
assert
central
problem
one
lack
diagnost
sophist
unten
data
africa
need
puzzl
pattern
infect
mac
caus
agent
leprosi
see
chapter
incred
slowgrow
parasit
macrophag
compar
purpos
may
use
recal
leishmania
infect
similar
cell
promin
opportunist
pathogen
patient
hiv
infect
import
cmi
leprosi
leishmaniasi
emphas
turk
bryceson
detail
comparison
skin
lesion
histopatholog
diseas
moreov
immunopatholog
infect
similar
view
widespread
preval
leprosi
tropic
subtrop
immunosuppress
effect
hiv
aid
leprosi
would
expect
becom
readili
appar
littl
evid
interact
fact
comprehens
analysi
possibl
interact
hivaid
leprosi
luca
conclud
leprosi
appear
anoth
miss
infect
aid
sever
studi
examin
posit
serolog
hiv
newli
diagnos
leprosi
case
one
report
rural
hospit
zambia
found
higher
preval
reactor
compar
blood
donor
surgic
patient
versu
number
small
control
adequ
match
larger
studi
hiv
seropreval
northwest
tanzania
new
leprosi
case
compar
control
found
presenc
hiv
antibodi
significantli
associ
multibacillari
diseas
fact
associ
base
hivposit
case
multibacillari
diseas
illustr
complex
epidemiolog
analysi
diseas
leprosi
anoth
comparison
seroposit
hiv
carri
regimen
assess
clinic
serolog
measur
includ
lack
appropri
nontreponem
titer
reduct
serolog
relaps
higher
rate
serolog
failur
continu
report
posthaart
era
becom
clear
effect
suppress
hiv
viremia
clearli
increas
rate
serolog
respons
standard
therapi
concern
effect
standard
therapi
syphili
hivposit
individu
base
larg
case
report
retrospect
studi
amplifi
disconcert
find
pallidum
invas
cn
earli
syphili
hivinfect
patient
earli
invas
cn
occur
equal
frequent
hivseroposit
seroneg
peopl
howev
atyp
cours
syphili
wellknown
preaid
era
knowledg
actual
frequenc
rel
signific
event
await
welldesign
prospect
studi
three
studi
provid
evid
clinic
present
clinic
serolog
respons
treatment
syphili
may
appreci
alter
hiv
coinfect
major
caveat
studi
mean
level
immunosuppress
patient
studi
assess
tcell
count
sever
furthermor
number
patient
involv
rel
small
thu
clinic
cours
syphili
face
sever
hivinduc
immunosuppress
may
fact
exacerb
respons
convent
therapi
may
lead
infrequ
occurr
seriou
advers
treatment
outcom
clinic
approach
hiv
patient
infect
cosmopolitan
sexual
transmit
diseas
thoroughli
discuss
elsewher
like
continu
evolv
whether
hiv
infect
deleteri
effect
cours
nonvener
endem
treponematos
see
chapter
unknown
effect
postul
analog
syphili
effect
hiv
concurr
infect
borrelia
speci
caus
relaps
fever
report
see
chapter
whether
lyme
diseas
follow
unusu
cours
hivinfect
peopl
unclear
final
initi
observ
suggest
leptospirosi
see
chapter
run
similar
cours
patient
coinfect
hiv
among
rickettsia
relat
organ
infect
coxiella
burnetii
etiolog
agent
q
fever
see
chapter
ehrlichia
spp
report
exacerb
concurr
hiv
infect
notabl
pathogen
oblig
intracellular
parasit
monocyt
macrophag
c
burnetii
live
multipli
phagolysosom
monocytemacrophag
host
defens
appear
depend
specif
tcell
activ
microbicid
effector
function
infect
cell
case
seri
suggest
patient
immunocompromis
due
varieti
caus
includ
leukemia
hodgkin
diseas
bone
marrow
renal
transplant
alcohol
suscept
symptomat
acut
relaps
chronic
diseas
c
burnetii
rational
expect
frequent
seriou
diseas
hivinfect
patient
clear
support
data
spars
studi
southern
franc
demonstr
threefold
higher
preval
antibodi
c
burnetii
hivseroposit
peopl
suggest
increas
rate
transmiss
hivinfect
peopl
found
seropreval
studi
pari
spain
central
african
republ
given
differenti
preval
risk
factor
acquisit
hiv
infect
studi
contradictori
data
strongli
suggest
c
burnetii
bloodborn
intraven
drug
use
risk
transmiss
two
studi
southern
europ
suggest
hiv
infect
lead
higher
diseasetoinfect
ratio
c
burnetii
retrospect
serolog
studi
patient
acut
q
fever
area
spain
high
incid
hiv
c
burnetii
infect
reveal
overrepresent
hivinfect
peopl
howev
endocard
common
present
clinic
featur
q
fever
appear
vari
hivinfect
uninfect
host
howev
definit
statement
await
prospect
studi
sever
immunosuppress
aid
patient
underli
damag
kansasii
second
mac
among
nontubercul
mycobacteria
caus
diseas
hivinfect
patient
unit
state
although
kansasii
report
caus
pulmonari
diseas
area
world
case
report
hiv
coinfect
north
america
europ
howev
coinfect
may
especi
preval
gold
mine
transvaal
south
africa
hivinfect
individu
diseas
due
kansasii
tuberculosi
similar
clinic
radiolog
characterist
major
differ
epidemiolog
prognost
implic
kansasii
diseas
tend
occur
later
cours
hiv
infect
mean
tcell
count
time
present
approxim
present
pulmonari
diseas
alon
dissemin
diseas
incid
industri
countri
plummet
haart
era
nontubercul
mycobacteria
differenti
colon
contamin
diseas
problemat
mere
colon
respiratori
tract
kansasii
appear
infrequ
aid
patient
howev
pulmonari
isol
taken
serious
despit
rel
vitro
resist
isoniazid
recommend
therapi
isoniazid
rifampin
ethambutol
therapi
clearli
alter
surviv
patient
pulmonari
diseas
dissemin
diseas
particularli
poor
prognosi
malmoens
uncommon
caus
pulmonari
diseas
resembl
tuberculosi
environment
reservoir
unknown
persontoperson
transmiss
never
document
multisystem
diseas
bacteremia
rare
occur
presenc
profound
immunosuppress
includ
sever
patient
aid
low
tcell
count
pulmonari
gi
diseas
along
bacteremia
usual
vitro
suscept
test
correl
well
clinic
respons
best
regimen
pulmonari
diseas
nonimmunosuppress
patient
appear
isoniazid
rifampin
ethambutol
optim
therapi
aid
patient
unclear
haemophilum
caus
local
lymphaden
immunolog
healthi
children
cutan
osteoarticular
rare
pulmonari
dissemin
diseas
immunocompromis
patient
sever
case
report
aid
patient
cutan
lesion
includ
furuncl
abscess
papul
vesicl
deep
ulcer
lesion
usual
diffus
often
extrem
cultur
demand
supplement
media
iron
sourc
vitro
suscept
data
scatter
clinic
report
suggest
rifampin
plu
ciprofloxacin
reason
empir
therapi
agent
good
activ
includ
amikacin
ciprofloxacin
clarithromycin
environment
sourc
mode
infect
unclear
sever
mycobacteria
demonstr
suspect
caus
opportunist
diseas
aid
patient
includ
fortuitum
primari
pulmonari
diseas
dissemin
diseas
cervic
lymphaden
along
genit
inflammatori
diseas
syphili
see
chapter
implic
cofactor
hiv
transmiss
mani
case
report
suggest
hiv
infect
alter
cours
diseas
treponema
pallidum
presenc
concurr
hiv
infect
syphili
thought
progress
frequent
rapidli
neurosyphili
lead
increas
incid
meningit
manifest
neurosyphili
lead
increas
frequenc
malign
secondari
syphili
ulcer
lesion
promin
system
symptom
less
amen
success
therapi
standard
approach
patient
hiv
coinfect
tropic
infecti
diseas
presenc
hiv
data
tropic
enter
bacteri
pathogen
scant
studi
slim
diseas
enteropath
aid
reveal
enter
bacteri
caus
case
preval
certain
enter
pathogen
campylobact
vibrio
enteropathogen
e
coli
tropic
accur
assess
detect
requir
use
special
media
experienc
laboratori
personnel
case
less
fastidi
organ
easier
detect
salmonella
spp
phenomenon
bacteremia
nontyphoid
organ
note
tropic
africa
sinc
bacteremia
shigella
spp
probabl
occur
commonli
patient
hiv
diseas
associ
may
expect
occur
tropic
well
report
evid
suggest
cholera
alter
presenc
hiv
although
gastric
secretori
failur
occur
commonli
aid
may
lead
greater
suscept
infect
vibrio
cholera
note
although
live
oral
cholera
vaccin
consid
contraind
peopl
hiv
infect
us
public
health
servic
usph
infecti
diseas
societi
america
idsa
work
group
shown
safe
immunogen
hivinfect
adult
mali
although
data
hiv
infect
epidem
meningococc
mening
provid
evid
signific
interact
studi
suggest
hiv
infect
may
risk
factor
sporad
meningococc
diseas
interact
hiv
bacillu
anthraci
yersinia
pesti
report
global
endem
bartonella
speci
b
hensela
b
quintana
see
chapter
caus
acut
persist
bacteremia
well
local
tissu
infect
includ
bacillari
angiomatosi
bacillari
peliosi
microscop
abscess
format
lymphaden
primarili
aid
patient
immunocompromis
peopl
close
relat
speci
b
bacilliformi
geograph
restrict
andean
river
valley
caus
similar
spectrum
diseas
includ
acut
persist
bacteremia
hemangiomat
nodul
resembl
seen
bacillari
angiomatosi
immunolog
normal
host
see
chapter
case
coinfect
hiv
b
bacilliformi
appear
report
hemorrhag
fever
virus
arbovirus
other
signific
interact
well
document
hiv
bunyavirus
hantavirus
phlebovirus
arenavirus
alphavirus
filovirus
part
cours
may
function
lack
suffici
experi
coinfect
agent
among
flavivirus
two
uncontrol
seri
patient
st
loui
enceph
texa
suggest
possibl
ratio
diseas
infect
cours
symptomat
diseas
worsen
presenc
hiv
infect
insuffici
data
determin
whether
hiv
alter
cours
yellow
fever
case
report
mortal
absenc
coinfect
west
nile
viru
infect
hand
case
report
interestingli
genet
data
implic
hiv
coreceptor
resist
symptomat
west
nile
viru
infect
dengu
infect
hand
case
report
interestingli
one
report
suggest
dengu
fever
like
acut
measl
scrub
typhu
may
lead
revers
suppress
hiv
replic
liveattenu
yellow
fever
vaccin
given
infect
hiv
theoret
risk
vaccineinduc
enceph
andor
hepat
damag
due
prolong
viremia
immunodefici
hand
case
postvaccini
enceph
multipleorgan
failur
yellow
fever
vaccineassoci
viscerotrop
diseas
report
presum
immunocompet
patient
denomin
approxim
million
peopl
vaccin
note
vaccine
develop
yellow
fever
vaccineassoci
viscerotrop
diseas
undergon
thymectomi
thymoma
rais
concern
tcell
defici
may
risk
factor
human
monocyt
ehrlichiosi
hme
caus
tickborn
agent
ehrlichia
chaffeensi
acut
febril
ill
associ
leukopenia
thrombocytopenia
hepat
enzym
abnorm
see
chapter
report
infect
e
chaffeensi
unit
state
report
infect
mali
support
much
wider
distribut
diseas
howev
hme
appear
aidsrel
oi
report
hospit
case
high
rate
complic
mortal
approxim
compar
estim
casefat
rate
hme
absenc
hiv
patient
fatal
diseas
tcell
count
less
patient
less
mortal
rate
report
case
diseas
caus
e
ewingii
relat
tickborn
agent
occur
patient
immun
defici
includ
hiv
infect
suspicion
thu
strong
e
ewingii
opportunist
pathogen
set
hiv
infect
case
infect
tickborn
agent
human
granulocyt
ehrlichiosi
face
hiv
infect
appear
report
evid
implic
spot
fever
typhu
group
rickettsia
clinic
signific
interact
hiv
prospect
studi
scrub
typhu
due
orientia
formerli
rickettsia
tsutsugamush
reveal
increas
clinic
sever
time
present
hivinfect
patient
median
tcell
count
interestingli
rickettsemia
occur
significantli
less
often
hivseroposit
patient
neither
rel
preval
infect
respons
treatment
address
studi
interest
acut
infect
tsutsugamushi
associ
decreas
plasma
hiv
viral
load
brucella
caus
system
diseas
worldwid
brucella
speci
facult
intracellular
parasit
infect
multipli
macrophag
see
chapter
cmi
respons
particularli
activ
monocyt
macrophag
antigenspecif
cell
import
host
resist
despit
meager
publish
data
coinfect
support
signific
effect
hiv
infect
brucella
fact
prior
aid
pandem
case
brucellosi
immunocompromis
host
hairi
cell
leukemia
igm
defici
report
retrospect
seropreval
studi
found
signific
associ
brucella
serolog
hiv
serolog
cohort
femal
sex
worker
kenya
clinic
cours
brucellosi
report
case
concurr
hiv
infect
outsid
spectrum
diseas
seen
normal
host
melioidosi
see
chapter
appear
behav
aidsrel
oi
diseas
endem
southeast
asia
particularli
northern
thailand
preval
aid
high
howev
one
case
fatal
recrudesc
bacterem
diseas
hivseroposit
person
report
anoth
studi
region
fail
note
differ
sever
ill
hiv
infect
individu
compar
hivuninfect
subject
clinic
seri
thailand
silent
regard
presenc
melioidosi
aid
patient
studi
bloodstream
infect
hospit
northern
thailand
report
similar
proport
b
pseudoma
llei
isol
hivinfect
uninfect
patient
sever
enter
bacteri
infect
report
caus
diseas
greater
sever
invas
chronic
recurr
presenc
hiv
coinfect
enterotoxigen
escherichia
coli
describ
caus
sever
diseas
hivseroposit
patient
shigella
speci
salmonella
campylobact
listeria
monocytogen
implic
caus
sever
relaps
diseas
hiv
infect
hiv
seroposit
found
differ
clinic
present
complic
mortal
hivinfect
compar
uninfect
children
measl
howev
enrol
base
clinic
diagnosi
measl
would
expect
minim
abil
detect
differ
clinic
present
bia
enrol
critic
ill
children
die
soon
admiss
significantli
greater
mortal
among
hivinfect
compar
uninfect
children
among
clinic
diagnos
oppos
confirm
measl
earli
death
prior
mount
diagnost
measl
igm
titer
face
sever
immunosuppress
suspect
confound
inde
extens
enrol
studi
reveal
hiv
coinfect
led
twofold
increas
measl
mortal
posit
find
studi
includ
higher
proport
hiv
infect
among
children
hospit
measl
expect
matern
popul
preval
rate
greater
proport
coinfect
patient
hospit
measl
younger
age
month
longer
durat
ill
hospit
longer
hospit
coinfect
children
followup
studi
shown
coinfect
patient
higher
risk
vs
prolong
day
rash
onset
shed
measl
viru
vivo
hiv
replic
suppress
acut
measl
therapi
rigor
studi
vitamin
shown
protect
sever
measl
malnourish
children
may
benefit
especi
given
margin
nutrit
statu
mani
hiv
infect
ribavirin
shown
reduc
sever
measl
normal
host
report
use
hivposit
patient
measl
pneumon
suggest
efficaci
although
rigor
data
lack
intraven
use
probabl
effect
intraven
immunoglobulin
ivig
may
also
benefit
given
sever
measl
hiv
patient
prevent
key
postexposur
prophylaxi
intramuscular
immunoglobulin
attenu
diseas
normal
host
recommend
acip
symptomat
hiv
patient
tcell
count
regardless
measl
serostatu
may
limit
efficaci
immunosuppress
patient
recommend
dose
mlkg
ml
maximum
given
intramuscularli
within
better
day
postexposur
prophylaxi
also
recommend
american
academi
pediatr
aap
hivinfect
children
adolesc
children
unclear
infect
statu
born
hivinfect
women
regardless
measl
immun
statu
degre
immunosuppress
preexposur
prophylaxi
monthli
ivig
advoc
hivposit
children
document
measl
vaccin
nonrespons
commun
outbreak
measl
like
econom
viabl
option
resourcepoor
area
tropic
measl
heavili
endem
vaccin
remain
princip
strategi
prevent
measl
hivinfect
peopl
normal
host
protect
efficaci
measl
vaccin
greater
vaccin
efficaci
data
hivseroposit
peopl
lack
seroconvers
data
avail
adult
hiv
infect
appear
wane
measl
antibodi
titer
increas
immunosuppress
unfortun
clear
data
respons
vaccin
adult
lack
antibodi
measl
children
situat
differ
hivinfect
infant
lower
rate
seroconvers
measl
vaccin
gener
lower
titer
antibodi
seroconvers
high
rate
secondari
vaccin
failur
antibodi
titer
decreas
time
increas
immunosuppress
absenc
haartrel
immun
reconstitut
respons
second
dose
vaccin
face
immun
suppress
gener
poor
like
benefit
vaccin
earli
month
age
lower
level
passiv
transfer
antibodi
infant
born
hivinfect
mother
less
hivrel
immunosuppress
earli
age
immun
strategi
clearli
immunogen
greater
percentag
hivinfect
compar
hivuninfect
infant
still
remain
measlessuscept
singl
case
also
report
fatal
myeloenceph
vaccin
thai
man
asymptomat
hiv
infect
albeit
low
tcell
count
high
viral
load
approxim
asymptomat
hivseroposit
us
militari
personnel
receiv
yellow
fever
vaccin
prior
introduct
routin
hiv
screen
advers
effect
detect
r
redfield
person
commun
small
publish
seri
travel
suggest
safeti
variabl
efficaci
yellow
fever
vaccin
hiv
seroposit
without
sever
immunosuppress
concept
bolster
retrospect
analysi
patient
swiss
hiv
cohort
studi
receiv
yellow
fever
vaccin
might
expect
latter
studi
note
reduc
vaccin
immunogen
rapid
declin
titer
neutral
antibodi
hiv
infect
immunogen
yellow
fever
vaccin
also
note
sever
reduc
absenc
signific
advers
event
hivinfect
children
divoir
recommend
use
yellow
fever
vaccin
hivseroposit
patient
asymptomat
remain
part
epi
pend
studi
yellow
fever
vaccin
recommend
symptomat
hivinfect
patient
acip
recommend
hivinfect
peopl
without
aid
symptomat
manifest
hiv
infect
laboratoryestablish
verif
adequ
immun
function
avoid
potenti
exposur
yellow
fever
offer
choic
vaccin
genet
evid
implic
disrupt
rant
axi
previous
healthi
hivuninfect
vaccine
develop
viscerotrop
diseas
vaccin
would
prudent
avoid
vaccin
patient
receiv
antagonist
given
appar
reduc
vaccin
effici
neutral
antibodi
titer
probabl
measur
prior
travel
travel
requir
oppos
actual
risk
infect
reason
vaccin
asymptomat
hivinfect
person
vaccin
waiver
letter
accept
border
obtain
travel
avoid
area
transmiss
travel
area
essenti
conscienti
avoid
mosquito
exposur
prudent
measl
viru
see
chapter
caus
annual
mortal
tropic
far
excess
due
tradit
tropic
diseas
virus
fact
quit
recent
worldwid
yearli
mortal
due
measl
rival
among
singl
pathogen
falciparum
malaria
tb
aid
mortal
predominantli
subsaharan
africa
similar
aid
infect
measl
viru
accompani
mark
abnorm
cmi
contribut
increas
suscept
secondari
infect
account
much
morbid
mortal
diseas
measl
exacerb
presenc
hiv
coinfect
mortal
rate
north
american
case
seri
report
measl
hivposit
children
adult
far
higher
usual
case
fatal
rate
seen
unit
state
although
present
diseas
normal
mani
rash
report
giant
cell
pneumon
princip
complic
prime
caus
death
although
fatal
subacut
measl
enceph
also
describ
tcell
count
report
mani
case
report
gener
less
case
report
seri
obvious
like
bias
toward
sever
end
spectrum
diseas
howev
four
substanti
studi
investig
hivmeasl
coinfect
subsaharan
africa
studi
children
hospit
measl
kinshasa
show
similar
mortal
rate
among
hivseroposit
seroneg
children
fact
sever
ill
patient
complic
hospit
like
obviat
abil
detect
differenti
mortal
studi
initi
studi
children
measl
lusaka
reveal
significantli
higher
mortal
rate
hiv
seroposit
seroneg
second
prospect
studi
hospit
children
lusaka
distinguish
approach
patient
hiv
coinfect
tropic
infecti
diseas
face
hiv
infect
includ
mandatori
use
rabi
immunoglobulin
use
intramuscular
vaccin
monitor
neutral
antibodi
titer
revaccin
may
necessari
even
multiplesit
doubledos
postexposur
vaccin
led
poor
respons
face
hiv
coinfect
presenc
immunosuppress
evid
hiv
infect
alter
outcom
infect
polioviru
see
chapter
estim
hivinfect
children
receiv
live
oral
polio
vaccin
opv
two
case
vaccineassoci
paralyt
poliomyel
hivinfect
children
report
greater
risk
vaccineassoci
diseas
face
hiv
infect
attribut
risk
thought
low
opv
remain
part
expand
program
immun
children
acip
recommend
replac
oral
polio
vaccin
inactiv
polio
vaccin
vaccine
unit
state
chronic
diarrhea
common
problem
aid
patient
throughout
world
although
definit
pathogen
role
ascrib
enter
virus
small
round
structur
virus
enter
adenovirus
coronavirus
aidsrel
diarrhea
either
north
america
africa
preliminari
data
suggest
greater
diseas
sever
children
coinfect
hiv
astrovirus
associ
picobirnavirus
diarrhea
hivcoinfect
patient
noncholeraendem
area
tropic
rotaviru
probabl
princip
caus
diarrheal
death
hivuninfect
infant
rotaviru
diarrhea
appear
opportunist
pathogen
children
hiv
coinfect
larg
studi
malawi
differ
sever
rotaviru
gastroenter
found
hivinfect
uninfect
children
interestingli
rotaviru
less
frequent
detect
hivinfect
children
gastroenter
despit
equal
resolut
clinic
diseas
howev
frequenc
death
hospit
discharg
significantli
greater
coinfect
children
infect
hepat
viru
hav
see
chapter
occur
worldwid
resourcepoor
countri
especi
tropic
hav
hyperendem
exposur
essenti
univers
age
year
virtual
adult
immun
hivhav
coinfect
appear
associ
higher
hav
serum
viral
load
longer
durat
viremia
lower
elev
serum
alanin
aminotransferas
level
similar
diseas
cours
vaccin
hav
safe
hivinfect
patient
efficaci
wane
increas
immunosuppress
cdc
nation
institut
health
nih
hiv
medicin
associ
hivma
idsa
recommend
vaccin
chronic
liver
diseas
msm
intraven
drug
user
hepat
asuscept
hivinfect
person
risk
factor
hav
infect
infect
hepat
e
viru
hev
see
chapter
local
sporad
epidem
diseas
report
mexico
north
west
africa
middl
east
south
southeast
east
asia
clinic
diseas
occur
adult
children
data
clear
whether
hev
signific
interact
hiv
cosmopolitan
hepat
virus
capabl
caus
chronic
diseas
howev
sever
potenti
import
interact
hiv
describ
preval
coinfect
further
fact
virus
share
rout
transmiss
hiv
hepat
b
viru
hbv
see
chapter
cmi
respons
thought
import
resolut
acut
diseas
product
hepat
inflamm
chronic
diseas
hiv
infect
report
lead
least
threefold
increas
risk
develop
chronic
hbv
carrier
state
invers
correl
count
without
signific
chang
sever
acut
diseas
potenti
reactiv
quiescent
hbv
infect
increas
hbv
safeti
concern
obvious
great
import
use
liveattenu
vaccin
hiv
patient
use
measl
vaccin
appear
quit
safe
hivinfect
children
adult
although
two
report
emphas
need
caution
man
hivrel
symptom
tcell
count
enumer
receiv
second
dose
measl
vaccin
prior
entri
colleg
one
year
vaccin
develop
progress
vaccineassoci
measl
pneumon
studi
effect
hiv
measl
mortal
children
hospit
measl
lusaka
zambia
also
troubl
previou
studi
suggest
prior
measl
vaccin
prevent
diseas
reduc
sever
infect
hivseroneg
boy
hospit
measl
prior
measl
vaccin
lead
significantli
lower
casefat
rate
although
case
fatal
rate
significantli
lower
vaccin
hivseroposit
boy
hivseroneg
girl
unvaccin
control
trend
toward
lower
case
fatal
rate
vaccine
surprisingli
howev
case
fatal
rate
higher
measlesvaccin
unvaccin
hivseroposit
girl
although
reach
statist
signific
reminisc
experi
hightit
edmonstonzagreb
ez
vaccin
use
hightit
ez
vaccin
less
month
age
associ
delay
excess
mortal
sever
studi
site
occur
exclus
femal
infant
reason
remain
unclear
notabl
zambian
studi
note
previous
highest
mortal
seen
youngest
vaccin
hivseroposit
girl
howev
region
measl
transmiss
riskbenefit
analysi
clearli
favor
measl
immun
children
regardless
hiv
statu
region
measl
transmiss
occur
immun
statu
monitor
withhold
measl
vaccin
hivinfect
children
sever
immun
compromis
wise
recommend
measl
vaccin
children
develop
countri
regardless
hiv
infect
symptom
statu
high
risk
sever
measl
gener
countri
unit
state
usphsidsa
work
group
advisori
committe
immun
practic
acip
recommend
measl
vaccin
hivinfect
peopl
accord
schedul
condit
normal
host
sever
immunocompromis
addit
risk
benefit
vaccin
immunoglobulin
prophylaxi
weigh
sever
immunocompromis
patient
increas
risk
due
travel
outbreak
aap
recommend
hivinfect
infant
young
adult
unit
state
includ
immun
face
sever
immunosuppress
use
measlesmumpsrubella
mmr
vaccin
month
age
second
dose
given
soon
day
first
dose
measl
transmiss
commun
vaccin
infant
young
month
old
mmr
monoval
measl
vaccin
revaccin
mmr
month
vaccin
measlessuscept
household
member
hivinfect
person
use
immunoglobulin
prophylaxi
note
previous
data
avail
paramyxovirus
aid
respiratori
syncyti
viru
infect
pneumonia
may
common
bronchiol
wheez
viral
carriag
may
also
prolong
copathogen
may
occur
frequent
normal
host
metapneumoviru
infect
emerg
data
suggest
higher
rate
hospit
bacteri
coinfect
mortal
hivcoinfect
infant
human
rabi
see
chapter
occur
tropic
countri
canin
rabi
still
endem
present
rabi
appear
alter
hiv
infect
hivinfect
immunosuppress
children
adult
clearli
substandard
respons
rabi
vaccin
howev
recommend
postexposur
prophylaxi
replic
decreas
inflamm
without
chronic
hepat
decreas
respons
hbv
vaccin
loss
hbv
antibodi
time
increas
rate
cirrhosi
liverrel
mortal
increas
risk
hepatocellular
carcinoma
vaccin
hbv
reason
efficaci
hivseroposit
popul
interestingli
howev
highest
report
rate
develop
chronic
carrier
statu
adult
occur
hivinfect
peopl
vaccin
time
develop
hbv
infect
hbv
appear
signific
effect
clinic
cours
hiv
infect
coinfect
hepat
c
viru
hcv
see
chapter
hiv
associ
reduc
likelihood
spontaneu
clearanc
increas
hcv
viral
set
point
increas
risk
cirrhosi
reduc
likelihood
success
respons
treatment
haart
era
hcvinduc
liver
diseas
becom
lead
caus
mortal
hivinfect
person
whether
hcv
infect
signific
effect
natur
histori
hiv
infect
respons
haart
remain
controversi
matern
hcv
infect
appear
associ
increas
risk
hiv
vertic
transmiss
data
hepat
viru
hdv
meager
hdv
replic
may
prolong
reactiv
presenc
hiv
coinfect
herpesvirus
see
chapter
industri
world
herp
zoster
quit
common
adult
aid
patient
tropic
histori
shingl
report
aid
patient
africa
area
africa
hiv
high
seropreval
posit
predict
valu
histori
shingl
hiv
infect
greater
elsewher
zoster
tend
develop
earli
hiv
diseas
recurr
common
chronic
genit
herp
simplex
lesion
common
throughout
world
patient
sexual
transmit
hiv
infect
cmv
infect
ubiquit
tropic
report
incid
sever
diseas
due
cmv
aid
africa
asia
although
latin
america
caribbean
lag
behind
industri
north
howev
like
greater
mortal
earlier
stage
diseas
natur
histori
diagnosi
therapi
diseas
due
coinfect
cosmopolitan
herpesvirus
discuss
elsewher
endem
central
africa
aidsrel
classic
posttranspl
kaposi
sarcoma
close
associ
human
herpesviru
aid
era
kaposi
sarcoma
becom
one
lead
malign
area
subsaharan
africa
singl
case
report
sever
acut
respiratori
syndrom
coronaviru
infect
face
hiv
coinfect
within
describ
clinic
spectrum
newli
emerg
viru
cdcnihhivmaidsa
work
group
updat
guidelin
prevent
oi
hivinfect
peopl
sever
factor
weigh
gener
evidencebas
recommend
diseas
incid
diseas
sever
term
morbid
mortal
level
immunosuppress
diseas
like
occur
feasibl
efficaci
cost
prevent
measur
impact
intervent
qualiti
life
toxic
drug
interact
potenti
drug
resist
qualiti
evid
support
recommend
prevent
oi
evalu
standpoint
prevent
exposur
prevent
first
episod
diseas
primari
prophylaxi
prevent
diseas
recurr
secondari
prophylaxi
discontinu
prophylaxi
whose
tcell
count
risen
respons
haart
guidelin
address
specif
recommend
pathogen
